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ABSTRACT 
 
Purpose: The Canadian Government has approved Bill C-45 to legalize and regulate the 
production, sale, and use of non-medical cannabis. Certain subpopulations, including those with 
psychiatric disorders, need to be uniquely considered during policy development and continually 
monitored as they may be particularly vulnerable to negative outcomes associated with cannabis 
use. This research was conducted to evaluate current prevalence and patterns of past 30-day 
cannabis use among individuals admitted to inpatient psychiatry in Ontario.  
 
Methods: This study evaluated patterns of past 30-day cannabis use among individuals admitted 
to inpatient psychiatry in Ontario, Canada from 2006 to 2016 (n=160322). An individual’s first 
admission during the study period (index admission) was used for the analysis. Prevalence rates 
were established, and trends were stratified by age, sex, and psychiatric diagnosis. Variables 
significantly associated with past 30-day use at the bivariate level were identified. Block 
modelling was carried out with significant variables to construct a logistic regression model that 
describes characteristics associated with past 30-day use. This process was repeated for 30-day 
readmissions. Cannabis was added to the final model to determine whether it remained 
significantly associated with readmissions after controlling for other variables. Factors associated 
with readmissions among past 30-day cannabis users and non-users were identified. 
 
Results: Past 30-day cannabis use increased from 15.4% to 25.3% from 2006 to 2016. Although 
more males reported past 30-day cannabis use, non-males had a greater increase in use across the 
study period. Persons ages 18 to 24 had the highest rates of cannabis use. However, older age 
categories also had increases in rates of use over time. Younger individuals with substance-
related and addictive disorders, males with schizophrenia and other psychotic disorders, and 
those with mood disorders all had greater odds of reporting past 30-day cannabis use, while a 
neurocognitive diagnosis was associated with reduced odds. Greater use was found among those 
with shorter lengths of stay, a history of violence, experiences of traumatic life events and 
financial hardship, poorer medication adherence, fewer lifetime psychiatric hospitalizations, and 
more severe symptoms and clinical measures (positive symptoms, social withdrawal, cognitive 
performance, mania symptoms, and indicators of addiction). After controlling for other variables, 
cannabis was significantly associated with readmissions for those exhibiting positive symptoms. 
Variables associated with readmissions for recent users were highly related to psychosis and may 
be associated with more complex and less compliant patients. 
 
Conclusions: A steady increase in past 30-day cannabis use from 2006 to 2016 was found. 
Continual monitoring of psychiatric admissions following legalization is important to determine 
whether an increase in cannabis use is associated with increased admissions. Several 
characteristics describing past 30-day cannabis users in inpatient psychiatry mimic that of users 
in the general population. Additional variables associated with past 30-day cannabis use were 
identified for the inpatient population which can be used to follow this population. Past 30-day 
cannabis use was significantly associated with 30-day readmissions for those exhibiting positive 
symptoms. Appropriate education and care planning is crucial in order to improve clinical 
outcomes and reduce unnecessary readmissions. 
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CHAPTER 1: INTRODUCTION AND OVERVIEW 
1.1 INTRODUCTION 
 The Federal government of Canada has passed legislation under Bill C-45, the Cannabis 
Act, that will legalize and regulate the production, sale, and use of non-medical cannabis. 
Although non-medical cannabis has been legalized in other jurisdictions, major Canadian 
political bodies and organizations, such as the Canadian Centre on Substance Abuse (CCSA) and 
the Task Force on Cannabis Legalization and Regulation (Task Force), have identified extensive 
knowledge gaps in cannabis research. This has contributed to a primarily precautionary approach 
being used to describe impending cannabis legislation. A number of research gaps need to be 
addressed to better anticipate and understand the potential individual and societal level impacts 
of legalization. This can help to measure and mitigate unanticipated consequences that may 
follow legalization. 
 To date, research on cannabis has been inconclusive and conflicting results have been 
produced in relation to mental health. Studies suggest that those with mental health conditions 
have higher rates of cannabis use than those without (1,2). Both the prevalence and impact of 
cannabis use among those with psychiatric illnesses have been shown to vary by both individual 
demographic and clinical characteristics, and between diagnostic groups. Despite high rates of 
use, use within this population may be problematic by exacerbating psychiatric symptoms and 
interfering with disease management.  Overall, there is a general lack of understanding and 
clarity on the relationship between cannabis use and mental health outcomes.  
 This research aimed to better understand the relationship between cannabis use and 
mental health conditions and how it affects clinical outcomes among those in care. This research: 
1) Explored trends in cannabis use amongst the general inpatient psychiatric population in 
Ontario, Canada from 2006 to 2016 
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2) Examined demographic and clinical characteristics associated with past 30-day cannabis use 
for individuals in inpatient psychiatry in Ontario  
 
3) Determined whether 30-day hospital readmission rates differed for individuals in inpatient 
psychiatry by past 30-day cannabis use status  
1.2 OVERVIEW 
 
 This thesis will be presented in six chapters. Chapter 1 has included a brief introduction 
of cannabis use and mental health and provides an overview of what is to come. Chapter 2 forms 
the literature review with subsections including: The Cannabis Sativa Plant: Botany and 
Pharmacology, Canadian Policy Context and Cannabis, Cannabis Use in The General 
Population, Cannabis Use and Vulnerable Populations, Cannabis Use and Clinical Outcomes, 
and Legalization in Other Jurisdictions. The study rationale is described in Chapter 3 to 
emphasize the importance of these research questions and the timely nature of this work. Chapter 
4 includes a description of the methods used during the analysis. Chapter 5 outlines the results 
produced through statistical analyses. Finally, a discussion of the study findings is included in 
Chapter 6.  
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CHAPTER 2: LITERATURE REVIEW 
2.1 THE CANNABIS SATIVA PLANT: BOTANY AND PHARMACOLOGY 
2.1.1 Cannabinoids and the Endocannabinoid System 
 Cannabis is derived from the leaves, flowers, stems and seeds of the cannabis sativa 
plant. Over 400 bioactive molecules have been identified in the cannabis plant, with at least 60 of 
them being cannabinoids (3). Cannabinoids induce physiological changes in the body by 
interacting with receptors of the endocannabinoid system (ECS) (3). The ECS is made up of 
three major components: cannabinoid receptors, endogenous ligands that interact with 
cannabinoid receptors, and enzymes that synthesize or degrade the ligands (4). As the primary 
function of the ECS is to regulate homeostasis in the body, this system is involved in a multitude 
of physiological processes. When cannabinoids interact with receptors of the ECS, users 
experience a diverse array of effects (Table 1).  
Table 1. The effects of tetrahydrocannabinol (THC) on the brain categorized by brain 
structure and function (5) 
BRAIN STRUCTURE REGULATES EFFECT OF THC 
Amygdala Emotional response, fear Panic/paranoia 
Basal ganglia Movement control Slowed reaction time 
Brainstem Sleep and arousal, 
temperature regulation, motor 
control 
Anti-nausea  
Cerebellum Motor coordination, balance Impaired coordination 
Hippocampus Learning and memory Impaired memory 
Hypothalamus Eating, sexual behaviour Increased appetite 
Neocortex Complex thinking, feeling, 
and movement 
Altered thinking, judgment, 
and sensation 
Nucleus accumbens Motivation and reward Euphoria  
Spinal cord Peripheral sensation Altered brain sensitivity 
 
There are two primary cannabinoid receptors in the ECS termed CB1 and CB2 receptors. 
CB1 receptors are predominantly concentrated in the central nervous system, including the brain 
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and spinal cord, where CB2 receptors are located in immune cells and neurons located 
throughout the body (6). Tetrahydrocannabinol (THC) and other cannabinoids elicit their effects 
by interacting with at least these two receptors. 
THC and cannabidiol (CBD) are the two cannabinoids that have been most extensively 
studied. THC is largely responsible for the psychoactive properties of cannabis, where CBD is a 
non-psychoactive constituent. The chemical structure of cannabinoids found in cannabis is 
similar to that of endocannabinoids, compounds found naturally in the body. Due to their 
structural similarity, cannabinoids are able to bind to the same receptors as endocannabinoids to 
elicit their respective pharmacological effects. For instance, when THC binds to cannabinoid 
receptors a sense of euphoria can be induced, or what users often refer to as a ‘high’, where CBD 
can produce a feeling of relaxation. Different strains of cannabis have differing ratios of THC 
and CBD meaning that the effects of cannabis vary by the strain of cannabis used (7). As THC 
and CBD are only two of many cannabinoids, much more research is needed to understand 
cannabis in its entirety. 
2.1.2 Cannabis and the Brain  
Knowing that the ECS is largely responsible for homeostatic regulation of the body, and 
that cannabinoids bind to the receptors of the ECS, we can begin to comprehend the array of 
effects experienced by cannabis users. When cannabis binds to receptors of the ECS, the 
homeostatic state of the body is interrupted. This can be explained by looking at how the ECS 
aids in regulating stress and emotion (8). Emotion is largely regulated in the hippocampal region 
of the brain. As many cannabinoid receptors are found in the hippocampus (9), cannabinoids can 
affect bodily processes regulated by this brain region. Thus, the effects of cannabis use on 
emotion may be explained by cannabinoids binding to the CB1 receptors found in the 
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hippocampus, ultimately affecting the homeostatic state of this area of the brain. As cannabinoid 
receptors are located in many brain regions and throughout the entire body, users experience 
diverse psychological and physiological effects. 
Individuals with mental health disorders may have a dysfunctional or altered 
endocannabinoid system (10). Some researchers have proposed that deficiencies in natural levels 
of cannabinoids may contribute to a susceptibility of developing post-traumatic stress disorder 
(PTSD) and depression (10). Bluett, Baldi, Haymer, Gaulden, Hartley, Parrish, et al (10) 
experimented in mice that were particularly vulnerable to higher levels of stress. They found that 
administering a low dose of THC helped with stress resilience and reduced anxiety symptoms by 
interacting with endogenous cannabinoid 2-arachidonoylglycerol in the amygdala and CB1 
receptors of the brain. Other researchers have contributed to this body of research and proposed 
that individual differences in the effects of cannabis on anxiety may be related to the availability 
of CB1 receptors in the right amygdala (11). Perhaps those with normal CB1 function experience 
adverse effects by hyperactivation of a normally functioning endocannabinoid system. Similar 
research should be conducted in distinct mental health conditions to explore the role that 
endocannabinoid dysfunction may play in psychological health outcomes, and to determine 
whether cannabis may help to restore normal function.  
2.1.3 Potency 
The effects of cannabis on an individual are dependent on multiple factors including the 
dose, the route of administration, use with other substances, the frequency of use, and the 
specific strain used (12). Over the past several decades the percentage of THC in cannabis plants 
has substantially increased. Some sources suggest a near tripling of THC percentage, from 4% to 
12% (13), where other sources suggested even greater increases from 1% to 9% over the same 
6 
 
time period (14,15). These findings suggest that over time cannabis users have been exposed to 
increasing levels of THC. As the concentration of THC increases, so too does the magnitude of 
the psychoactive effects.  
2.2 CANADIAN POLICY CONTEXT AND CANNABIS 
Canada is shifting away from non-medical cannabis prohibition to a legal framework. 
Cannabis became a controlled substance in Canada in 1923 when it was added to the 
Confidential Restricted List under the Narcotics Drug Act Amendment Bill. In April 2017, the 
Federal Government of Canada tabled legislation that focused on legalizing and heavily 
regulating non-medical cannabis. This legal framework has been based on the premise to 
“promote and protect the health, safety and human rights of their populations,” (16).  
2.2.1 Medical Cannabis Policy 
 Cannabis for medical purposes was approved for use in Canada in 2001. Since its initial 
approval, several pieces of legislation have been implemented and reformed to regulate the 
growth, distribution, and use of cannabis for medical purposes. In 2001 the Canadian federal 
government established the Medical Marihuana Access Regulations (MMAR) which was 
replaced in 2014 by the Marijuana for Medical Purposes Regulations (MMPR). These 
regulations differed in that the MMPR allowed doctors to prescribe cannabis to their patients, 
rather than requiring government authorization. The MMPR also resulted in a shift from a single-
producer system to a multi-producer system. In 2016 these regulations were again replaced with 
the current Access to Cannabis for Medical Purposes Regulations (ACMPR), which allowed 
cannabis to be obtained in additional forms to the dried marijuana plant (16). Although the 
government has allowed doctors to write medical documents (similar to a prescription), which 
permits patients to obtain cannabis for medical conditions, it is important to acknowledge that 
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Health Canada has not approved cannabis for therapeutic use (17). This has been mainly due to a 
lack of clarity on how safe and effective cannabis is for treating certain ailments. Thus, 
physicians have been left to prescribe a drug where no clear guidelines exist. As of December 
2017, there were 269,502 client registrations1 with medical licenced producers (18) and 115 
licensed producers that supply cannabis to users (19). 
 Typically, cannabis has been used for physical health disorders including glaucoma, pain 
management, arthritis and cancer. Although greater skepticism has been expressed towards 
cannabis being used for psychological disorders, emerging research has begun to suggest that 
CBD concentrates, specifically, may help with psychiatric symptoms in those with mental health 
disorders (20,21). It is important to gain further clarity for how cannabis interacts with specific 
mental health conditions, so that if it is found to beneficial, appropriate and clear guidelines can 
be given to users. It is imperative that the public is adequately informed about this research 
including what strains (e.g., pure CBD) may be beneficial for symptom management, and what 
diagnostic categories may benefit from CBD use versus those that may have adverse 
experiences. Failure to communicate this information may lead to individuals self-medicating 
with inappropriate cannabis strains that exacerbate, rather suppress, psychiatric symptoms.  
2.3 CANNABIS USE AND THE GENERAL POPULATION 
Cannabis is the most commonly used illicit drug in Canada. Results from the most recent 
Canadian Tobacco, Alcohol, and Drugs Survey (CTADS) show that 44.5% of Canadians aged 15 
and older report using cannabis at least once in their lifetime, 12.3% report using in the past year, 
and 8.8% report using in the past 3 months (22). Within the Canadian population, prevalence and 
                                                 
1 An individual can be registered with multiple licensed producers suggesting that some people 
may be double counted.  
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patterns of use have been shown to vary by individual-level factors. Use has been found to be 
more common among younger age cohorts; young adults aged 18 to 24 are the greatest users 
with approximately 30% reporting past year use, relative to 15 to 17-year olds (18%), 25 to 44 
(18%), 45 to 64 (7%) and 65 and older (1.6%) (23). Past-year use tends to be higher among 
males (15%) than females (10%) (23), and among individuals with a single relationship status 
(24). Although some Canadian surveys report that cannabis use has decreased over time (25), 
others have found an overall increase in cannabis use prevalence despite there being marked 
periods of decline (23).2 Consideration needs to be made when understanding trends in past 30-
day cannabis use in the general population as survey methods that collect information on 
substance use behaviours have changed considerably throughout time. 
2.4 CANNABIS AND VULNERABLE POPULATIONS 
2.4.1 Youth 
Use of cannabis at younger ages, particularly among those with high rates of 
consumption, has been associated with poorer health and social outcomes (26,27). As the brain 
continues to develop well into a person’s twenties (28), initiating cannabis use at a younger age 
may lead to lifelong biological changes. Patton, Coffey, Carlin, Degenhardt, Lynskey, and Hall 
(29) found cannabis use in early life to be associated with an increased risk of developing poor 
mental health in young adulthood; a dose-response relationship was established with heavier 
users having the poorest mental health outcomes. Other research has suggested that those who 
use cannabis in youth are also more likely to experience adverse social outcomes. For instance, 
                                                 
2 These patterns were assessed by combining results from a number of Canadian national surveys 
used over time to capture substance use behaviours.  The decreasing trend was found with the 
CAS and CADUMS surveys, while an increasing trend was found with results from nine 
different national surveys spanning from 1985 to 2015 (23).  
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Hall, Renstrom, and Poznyak (30) found that individuals who used cannabis daily in youth had 
poorer academic achievement, cognitive impairment, were more likely to use other illicit drugs, 
had an increased risk of depression, suicidal ideation and behaviour, and both psychosis and 
schizophrenia. These findings suggest that cannabis use among youth should be avoided. 
However, as demonstrated by 2015 CTADS results, younger cohorts make up the majority of 
cannabis users within the broader Canadian population. As research demonstrates that use among 
youth can have adverse lasting psychosocial implications, it is crucial that impending legislation 
informs the public about the risks and aims to protect this vulnerable population. 
2.4.2 Mental Health 
 The relationship between cannabis use and mental health has been widely explored but is 
not well understood; studies often report conflicting results and results that are incomparable due 
to varying study designs and methods. It is crucial to better understand whether those with 
mental health conditions as a whole are at risk of adverse effects, whether only certain diagnostic 
groups or individuals experience adverse effects, and what adverse effects might be experienced 
by cannabis users.  
 2.4.2.1 Cannabis use and psychosis 
 There is robust research exploring the relationship between cannabis use and psychosis. 
Cannabis use has been found to be higher among individuals with psychosis relative to rates of 
use in the general population. In a study examining individuals with psychosis, 66.2% reported 
using cannabis in their lifetime (31). This figure suggests that those with psychosis may have 
greater rates of use than the general Canadian population (see Section 2.3). Additionally, 
consistent evidence suggests that those who begin using cannabis earlier (32), who have heavier 
use (33), and who have a genetic predisposition (34) are at an increased risk of developing 
10 
 
psychosis. In those who already have an increased risk, cannabis users may also develop 
psychosis earlier compared to non-users (31).  
 Recent research controlling for socio-environmental and genetic factors has begun to 
support a causal relationship between cannabis and schizophrenia (35). These findings point to 
the idea that those who have an increased risk of schizophrenia should not be using cannabis. 
However, as evidenced by the high rates of reported use in a study by Foti, Kotov, Guey, and 
Bromet (31), those at risk of schizophrenia and other psychotic disorders are significant users of 
cannabis. Preventing use in those with or those at risk of psychotic disorders, and better 
understanding how use among this population relates to clinical outcomes, is vital for both 
disease prevention and disease management. 
2.4.2.2 Cannabis use and non-psychotic disorders 
 The relationship between non-psychotic disorders and cannabis use is less clear than 
findings for psychosis. There are inconsistencies regarding the strength and direction of the 
relationship between cannabis use and current and/or future risk of anxiety, depression and 
bipolar disorders. The prevalence of cannabis use among those with non-psychotic disorders has 
also not been established; studies have mainly focused on the prevalence of psychiatric illnesses 
among cannabis users, rather than on the prevalence of cannabis use among those with 
psychiatric illnesses.  
 A study by van Laar, van Dorsselaar, Monshouwer, and de Graaf (36) found that 18 to 
64-year olds who used cannabis had a greater risk of subsequent major depression (OR 1.62, 
95% CI: 1.06-2.48) and bipolar disorder (OR 4.98, 95% CI: 1.80-13.811). However, after 
controlling for confounders, they did not find any significant relationship between cannabis use 
at baseline and future anxiety disorders. A prospective study by Blanco, Hasin, Wall, Flórez-
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Salamanca, Hoertel, Wang, et al (37) found similar results with findings showing no relationship 
between cannabis use at Wave 1 and anxiety or mood disorders three years later at Wave 2. 
However, in a meta-analysis of prospective longitudinal studies, Lev-Ran, Roerecke, Le Foll, 
George, McKenzie and Rehm (38) found that cannabis use, particularly heavier use, was 
associated with the development of depression. Cannabis users had 1.2 times greater odds of 
developing depression than non-users, and heavy users had 1.6 greater odds of developing later 
depression compared to non-users and light users. 
In contrast to the previous studies, a prospective cohort study that examined cannabis use 
among Australian school children, Degenhardt, Coffey, Romaniuk, Swift, Carlin, Hall, et al (39) 
found cannabis use to be associated with anxiety but not depression. Cross-sectional analyses 
showed that those who used cannabis were 2.5 times more likely to report symptoms of anxiety 
(95% CI: 1.2-5.3). Individuals who used at least weekly during adolescence and who continued 
to use throughout the study period were also found to have greater odds of anxiety disorders (OR 
3.2, 95% CI: 1.1-9.2). However, no significant relationship was found between cannabis use and 
risk of current or future depression.  
Additional research has explored the relationship between cannabis use and PTSD (40). 
Individuals with PTSD have consistently been found to have increased rates of cannabis use and 
cite symptom relief as a reason for use. Those with a lifetime or current PTSD diagnosis have 
been found to be greater lifetime users of cannabis are more likely to be daily users (41-43). 
Mixed research has been produced on the efficacy of cannabis for treating PTSD. Some studies 
report that individuals with PTSD who use cannabis have self-reported improvements in their 
clinical symptoms (44). However, other researchers have criticized studies stating that the 
evidence quality is low due to uncontrolled study designs, non-representative and small samples, 
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lack of long-term follow-up, and potential confounding with pharmaceutical treatment (45,46). 
In summary, although those with PTSD have been found to be greater cannabis users, it is 
unclear whether it is suitable for first-line treatment.  
2.4.2.3 Summary  
Together, findings on the relationship between cannabis and anxiety, depression, bipolar 
disorders and PTSD have been inconsistent and are often in direct confliction with one another. 
This may, in part, result from varying study designs including the analysis of different study 
populations, types of mental health measures, definitions of cannabis use, and varying follow-up 
times. Additionally, these findings demonstrate the complexity and heterogeneity of specific 
diagnoses within broader psychiatric categories. For instance, the effects of cannabis on 
psychiatric outcomes may depend on the spectrum of diagnosis for some diagnostic categories 
(e.g., anxiety). A study by Zvolensky, Lewinsohn, Bernstein, Schmidt, Buckner, Seeley, et al 
(47) found cannabis to be associated with an increased futuristic risk of developing a panic 
disorder while other research found a beneficial relationship with social anxiety disorders (SAD) 
by other researchers (48).  
 The relationship between cannabis and mental health has been shown to be complex and 
dependent on a number of factors. Some findings suggest that the effects of cannabis use on an 
individual may vary by demographic factors, such as by sex and/or gender. Patton, Coffey, 
Carlin, Degenhart, Lynskey and Hall (29) found that those who used cannabis in adolescence had 
increased odds of developing later depression and anxiety. However, females who used daily had 
approximately 5 times greater odds (OR 5.6, 95% CI: 2.6-12) of reporting current depression and 
anxiety relative to males. These findings point to the importance of exploring these relationships 
not just at a population level, but also that demographic factors need to be considered. 
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Additionally, the conflicting evidence presented provides grounds for why studies with 
comparable study designs need to be produced; it can allow a better understanding of whether 
cannabis contributes to adverse mental health outcomes, or if there is no relationship at all.  
2.4.3 Theories for cannabis use 
Several theories have been proposed to explain why cannabis use is generally higher 
among those with mental health conditions than in the general population. The self-medication 
hypothesis proposes that individuals with mental conditions use cannabis as a means of symptom 
management; it states that higher rates of cannabis use are due to people with mental illnesses 
using cannabis for some specific reason, rather than cannabis inducing mental health conditions 
(symptom exacerbation hypothesis) (49). Studies have been conducted to evaluate the self-
medication hypothesis and have found that individuals with mental illnesses commonly report 
using cannabis to seek relief from their clinical symptoms. Schofield, Tennant, Nash, 
Degenhardt, Cornish, Hobbs, et al (50) found that the most common motivators for cannabis use 
in 49 individuals with psychosis included boredom, a social activity with friends, to aid with 
sleep issues, reducing anxiety and agitation, and to manage negative psychotic and depressive 
symptoms. Although some individuals have reported relief from cannabis, other research 
proposes that cannabis may induce adverse mental health states (49,51). Thus, although cannabis 
may be beneficial for some individuals, it may be problematic for others. This is why some 
researchers have suggested that perhaps cannabis was originally used as a form of self-
medication, but that prolonged exposure may actually exacerbate and worsen psychiatric 
conditions (52).  
Although cannabis has been understood to be related to worse clinical symptoms for 
some individuals, findings from emerging clinical studies suggest that cannabis may actually 
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have therapeutic benefits for mental health conditions. A study by Crippa, Derenusson, Ferrari, 
Wichert-Ana, Duran, Martin-Santos, et al (48) evaluated whether CBD could moderate anxiety 
in individuals with SAD. They found that those who took CBD, rather than a placebo, had lower 
levels of state anxiety prior to engaging in an anxiety-provoking situation. While these types of 
studies are somewhat novel, and the relationship is not entirely understood, the relief of clinical 
symptoms may be due to cannabis modulating dysfunction of the endocannabinoid system (53). 
As there may be some therapeutic potential of cannabis for those with mental health conditions, 
it may not be necessary to suggest that all individuals with mental health conditions entirely 
avoid cannabis. Further research is needed to evaluate the types of strains that may be beneficial, 
and whether this positive relationship is only seen for some diagnostic groups.  
Individuals who self-medicate with cannabis may not have a prescription and may obtain 
strains from unregulated sources (54). Self-medication with non-medically prescribed cannabis 
raises concern as it may pose a threat to symptom management. Cannabis from unregulated 
sources may interfere with an individual’s ability to obtain a strain with elevated CBD levels, 
and reduced THC content. Using the correct strain when trying to manage psychiatric symptoms 
is critical as higher CBD content has been noted to help with suppressing anxiety symptoms, 
while higher THC content may induce anxiety symptoms due to its known psychoactive 
properties (16). Medical cannabis prescribed by a physician may have more potential to aid with 
depression and anxiety as users have greater control over strain selection, while cannabis 
obtained from illegal markets may exacerbate undesirable symptoms due to reduced CBD 
content and ever-increasing THC percentage. It is imperative that the relationship between 
strains of cannabis and mental health outcomes is understood further and this information is used 
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to inform both policy and the general public to ensure that individuals are not self-medicating 
with unsuitable strains. 
2.5 CANNABIS USE AND CLINICAL OUTCOMES  
 Various studies have evaluated how cannabis relates to clinical outcomes such as length 
of stay (LOS), relapse3, severity of symptoms4, and readmissions. However, many have been 
criticized for failing to adjust for confounders, thus raising questions about the reliability and 
comparability of results. Additionally, research looking at clinical outcomes has primarily been 
conducted on individuals with psychotic disorders. This raises the question of whether findings 
can be generalized to the non-psychotic mental health population. Findings from different studies 
will be presented to demonstrate how research has been unsuccessful in producing consistent 
results and to demonstrate that more research is needed. 
2.5.1 Disease management: Treatment adherence and relapse 
 A systematic review by Zammit, Moore, Lingford-Hughes, Barnes, Jones, Burke, et al 
(55) evaluated 13 longitudinal studies to explore the relationship between cannabis use and 
clinical outcomes in those with psychosis. In this review, cannabis use was found to be 
consistently associated with increased rates of relapse and treatment non-adherence. However, 
they criticized many of these studies for failing to adjust for confounders. Barrowclough, Gregg, 
Lobban, Bucci, and Emsley (56) found partially conflicting results to this systematic review. 
They looked at the relationship between cannabis use and clinical outcomes including psychotic 
symptoms, affective symptoms, functioning, and relapse. They found no association between 
                                                 
3 Many of these studies defined relapse as being a change in symptom severity from baseline to 
follow-up measured using the Brief Psychiatry Rating Scale (BPRS).  
4 Symptom severity is based on scales such as the BPRS and the Positive and Negative 
Syndrome Scale.  
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cannabis use and negative or positive symptoms, relapse or hospital admissions, but that 
participants who changed their cannabis status from user to non-user had improved patient 
functioning and improvements in anxiety scores. Barbeito, Vega, de Aźua, Saenz, Martinez-
Cengotitabengoa, Gonzalez-Ortega, et al (57) also found that a change in cannabis status 
improves treatment adherence post-hospitalization in those with first-episode psychosis.  
 Some studies support the idea that cannabis users with mental illnesses are at greater risk 
of relapse. For instance, both Wade, Harrigan, Edwards, Burgess, Whelan, and McGorry (58) 
and Hides, Dawe, Kavanagh, and Young (59) found cannabis use to be associated with psychotic 
relapse in general. Among those specifically with schizophrenia, San, Bernardo, Gómez, and 
Peña (60) found cannabis consumption to be associated with relapse and abstinence from 
cannabis use to be protective against relapse. Schoeler, Petros, Di Forti, Klamerus, Foglia, 
Murray, et al (61) investigated medication adherence as a possible mediating factor between the 
use of cannabis and relapse among those with first-episode psychosis. They found that there was 
a strong relationship between continued cannabis use and the risk of relapse, number of relapses, 
length of relapse, and the time until relapse occurred. This relationship was found to be mediated 
by medication adherence. Those who relapsed throughout the study period were more likely to 
be continual cannabis users and to be non-adherent or irregularly adherent to their prescribed 
medication. This suggests that ensuring medication adherence may help to reduce the potential 
negative effects of cannabis use on clinical outcomes.  
 Together, the presented studies suggest that there is no clear answer for whether cannabis 
use can help or hinder treatment progression for those with mental health conditions. Exploring 
this relationship in a larger more representative sample is imperative in order to develop more 
concrete policy recommendations.  
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2.5.2 Length of Stay (LOS) 
 Consistent results have been produced in relation to hospital LOS for cannabis users. 
Studies have consistently concluded that cannabis users have shorter LOS than non-users. A 
study by Rylander, Winston, Medlin, Hull, and Nussbaum (62) found that cannabis users 
admitted to inpatient psychiatry had shorter LOS after adjusting for confounders when compared 
to those who did not use cannabis. Johnson, Wu, Winder, Casher, Marshall and Bostwick (63) 
found similar results among inpatients with schizophrenia, schizoaffective disorder or bipolar 
disorder with cannabis users having shorter LOS relative to non-users (10.9 days versus 15.9 
days).  
 Although shorter LOS may suggest that cannabis users have improved clinical outcomes, 
LOS cannot be assessed in isolation from other outcomes. If LOS is shorter but all other clinical 
outcomes are worse among cannabis users (e.g., relapse, severity of symptoms, treatment 
adherence), this may suggest that individuals are not effectively managing their mental health 
condition leading to the need for a readmission. The Canadian Institute for Health Information 
(CIHI) (64) found that those with concurrent substance use disorders (SUD) and mental health 
diagnoses have increased health resource use overall as they cumulatively spend more time in 
hospital despite shorter individual stays. CIHI’s study included all SUDs and therefore should be 
examined specifically in cannabis users and in those without SUDs.   
2.5.3 Readmissions 
Data from high-income countries including Europe, the USA, and Canada suggest that up 
to 13% of individuals in psychiatric inpatient units are readmitted shortly after discharge (65). 
However, not all individuals in inpatient psychiatry have an equal probability of being 
readmitted with certain demographic and clinical characteristics being more strongly associated 
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with risk of future readmission. Vigod, Kurdyak, Seitz, Herrmann, Fung, Lin, et al (66) and 
Perlman, Hirdes and Vigod (67) have identified several characteristics that independently predict 
an increased risk of readmission. These factors included having repeat admissions, having a 
history of harming oneself or others, the specific diagnosis including having a diagnosis of 
psychosis, bipolar and/or a personality disorder, having a secondary SUD diagnosis, having an 
unplanned discharge, the presence of a medical comorbidity, prior service use history, and length 
of hospital stay. Other characteristics associated with increased risk of readmission include being 
younger, having a forensic history, low familial support, more severe mental illness, acuity of 
symptoms at admission or discharge, and being discharged against medical advice (68). 
Although these characteristics were identified in general inpatient psychiatric populations, they 
may also predict the risk of readmission in the subpopulation of cannabis users. 
It is uncertain how readmissions rates for cannabis users compare to that of non-users.  
However, some researchers suggest that cannabis users do not have an increased risk of 
readmission following discharge. Rylander, Winston, Medlin, Hull, and Nussbaum (62) looked 
at the relationship between cannabis use and inpatient psychiatric hospital outcomes. Cannabis 
use was measured using urine toxicology screening. They found no difference in 30-day 
readmission rates in users versus non-users. Johnson, Wu, Winder, Casher, Marshall and 
Bostwick (63) also support this finding as they found that cannabis use among those admitted to 
inpatient psychiatry with a diagnosis of schizophrenia, schizoaffective disorder or bipolar 
disorder was not associated with hospital readmissions rates.  
2.5.4 Symptom Severity 
 Research has shown that cannabis use among those with psychosis complicates disease 
course. A study by Johnson, Wu, Winder, Casher, Marshall, and Bostwick (63) found that those 
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admitted to psychiatric inpatient units with a diagnosis of schizophrenia, schizoaffective disorder 
or bipolar who used cannabis were more likely to trigger the Positive and Negative Syndrome 
Scale. Fergusson, Horwood, and Swain-Campbell (69) also found that after adjusting for 
potential confounders, individuals meeting criteria for DSM-IV cannabis dependence had 
increased rates of psychotic symptoms compared to non-cannabis dependent individuals. 
However, Rylander, Winston, Medlin, Hull, and Nussbaum (62) found no difference in BPRS 
scores when looking at cannabis use among an inpatient psychiatric population. It is difficult to 
conclude whether cannabis affects psychotic symptoms as each of these studies used different 
scales to measure symptoms and included varying intensities of cannabis use. However, if 
individuals with psychosis who use cannabis have more severe symptoms, they may require 
greater support and come into contact with healthcare services more than non-cannabis users. 
 Each of the presented studies evaluated clinical outcomes among the inpatient population 
with psychotic disorders specifically. These studies cannot necessarily be generalized to the non-
psychotic population as the inherent diagnoses vary at the biological level and with respect to 
disease management and care. It is imperative that clinical outcomes are also observed among 
the non-psychotic inpatient population to evaluate how cannabis affects disease management and 
contributes to healthcare needs, and to determine whether cannabis should be discouraged among 
this group.  
2.6 LEGALIZATION IN OTHER JURISDICTIONS 
 Data from other jurisdictions that have recently legalized non-medical cannabis use can 
provide some insight into how this policy may impact rates of use among the general population. 
Research on the impact of legalization is limited due to the brief amount of time that has passed; 
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some researchers (70) note that there may be a 10-year gap between policy change and when 
changes in rates of use and harms of use can be accurately assessed.  
2.6.1 Rates of Use 
 Findings from Colorado show an approximate 6% increase in the number of individuals 
reporting cannabis use from 2008/2009 to 2014/2015 when non-medical cannabis use became 
legalized (71). In American states that have changed their cannabis laws, changes in patterns of 
use have not been uniform for all demographic groups. For instance, use has decreased among 
youth aged 12 to 17 but has increased in older age groups (72). Although crude increases have 
been reported, it is not known whether these numbers reflect actual increases in use or whether 
more people are willing to be honest about their cannabis use behaviours now that non-medical 
use of the drug is legally permitted. 
2.6.2 Public Health Impacts 
The impact that the legalization and regulation of non-medical cannabis will have on 
mental health outcomes is largely unknown. Some findings from American states that have 
legalized non-medical cannabis seem to indicate potentially adverse mental and public health 
outcomes. For instance, in Colorado, where non-medical cannabis was legalized in 2014, the 
prevalence of emergency department (ED) visits for concurrent mental illness and cannabis use 
was five times higher than visits for mental illness without cannabis use (73). Once non-medical 
cannabis use was legalized in Colorado, the Colorado Hospital Association reported a near 
doubling of ED visits due to cannabis exposure. These visits were largely due to accidental 
exposure from cannabis edibles. After 2014, ED visits with cannabis-related billing codes 
significantly decreased (73) suggesting that people may have learned safer consumption habits 
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over time. Overall, research within the mental health context has been limited with much 
research focusing on exposure in other vulnerable populations such as children.  
Early findings from other jurisdictions indicate that policy has insufficiently protected 
vulnerable populations from adverse effects of cannabis use. These results underscore the 
importance of monitoring the impact of Canadian cannabis legislation on vulnerable health 
populations, particularly those at risk or living with a mental health illness. Additionally, it 
demonstrates that more research is needed to understand how those who may be at increased 
risks of experiencing adverse effects from cannabis use can be protected. 
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CHAPTER 3: STUDY RATIONALE 
 Cannabis use has been identified as a potential risk factor that contributes to poor mental 
health outcomes and may complicate course of illness in those with a developed mental health 
condition. Within the Canadian population, prevalence of cannabis use across all mental illnesses 
has not been established. However, data from other jurisdictions have consistently found rates of 
cannabis use to be higher in individuals with mental illnesses relative to rates of use in the 
general population (1,2). It is crucial to understand how cannabis use relates to mental illness in 
the broad sense, but also how it relates to individual diagnoses so that this potentially vulnerable 
population can be protected. 
 A number of research and policy-related initiatives have helped to capture patterns and 
outcomes associated with cannabis use in the general population. For instance, information on 
cannabis use patterns are gathered annually using the Canadian Alcohol and Drug Use 
Monitoring Survey (CADUMS) and embedded CTADS surveys. These surveys have informed 
trends in cannabis use overtime and demographic profiles of those most likely to use cannabis at 
the population level. However, more research within the mental health population is needed as 
research has consistently identified this group as being more susceptible to experiencing adverse 
effects after cannabis use. Additionally, individuals with mental health conditions make up a 
large proportion of users within the general population. Exploring cannabis use amongst this 
population can give insight into how cannabis impacts not only individuals, such as by 
complicating disease course, but also broader society by contributing to higher healthcare needs 
and thus, higher healthcare costs. 
Major organizations and political bodies such as the CCSA and the Task Force have 
identified areas for future cannabis research. In a document discussing the need to further 
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understand health impacts of non-medical cannabis use, the CCSA presented explicit areas 
where large gaps in the literature still exist (74). In developing their recommendations for the 
federal government, the Task Force also identified several research gaps that will need to be 
filled before and after non-medical cannabis is legalized. This research addresses some of the 
knowledge gaps identified by the CCSA, such as increasing our understanding of how the effects 
of cannabis differ between individuals by demographic and individual factors, exploring the 
effects of cannabis in poly-substance users, and establishing baseline figures of current cannabis 
use in Canada. Specifically, within the inpatient psychiatric population we will be able to 
determine the prevalence and relationship of concurrent cannabis use and mental health 
disorders.  
Research Question 1 (RQ1): What are the trends in cannabis use amongst the general 
inpatient psychiatric population in Ontario, Canada from 2006 to 2016? 
 The first research question will establish baseline prevalence and patterns of past 30-day 
cannabis use within the broad inpatient psychiatric population. This will have important 
implications for tracking the prevalence of cannabis use among individuals using mental health 
services following cannabis legalization. These figures can be used to evaluate whether patterns 
of use and prevalence of use change following legalization. Changes in patterns of use can be 
explored in more depth, such as by demographic and clinical factors, to determine whether 
changes in patterns of use are concentrated within particular subpopulations, and whether these 
changes have any adverse impacts.   
Research Question 2 (RQ2): What demographic and clinical characteristics are associated 
with past 30-day cannabis use for individuals in inpatient psychiatry in Ontario? 
 The second research question identifies demographic and clinical characteristics of 
individuals in inpatient psychiatry most likely to be a past 30-day cannabis user. This population 
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can be evaluated to determine whether specific clinical features, demographics, or functional 
characteristics differ between those who use and do not use cannabis. Characteristics of 
individuals in inpatient psychiatry most likely to be users of cannabis can be monitored to 
evaluate whether these features change after legalization. If individual profiles change, it is 
important to monitor the impact on admissions and clinical outcomes. If cannabis is considered 
to be problematic in those most likely to be users, targeted interventions and policy efforts that 
aim to reduce use can be developed.  
Research Question 3 (RQ3): Do 30-day hospital readmission rates differ for individuals in 
inpatient psychiatry by past 30-day cannabis use status? 
 There have been inconsistent findings for how cannabis use influences clinical outcomes.  
Some findings suggest that use within the inpatient population negatively affects treatment 
outcomes and disease course, where others suggest that dimensions of care, such as LOS, are 
positively impacted (see Section 2.5). Research produced by CIHI (64) suggests that although 
those with concurrent SUDs and mental health diagnoses stay shorter in hospital per admission, 
relative to those with only a single mental health condition, they spend greater cumulative time 
in hospital due to more frequent readmissions. These relationships should be explored further, 
such as by examining cannabis users alone, as these findings cannot necessarily be generalized to 
this population due to the intensity of drugs included in this study (all drugs). 
 The third research question also identifies variables associated with readmissions in 
cannabis users and non-users. This information can be used to inform and develop targeted 
interventions that aim to reduce readmission risk in both of these subpopulations. Overall, 
reducing readmission rates and streamlining care is important to improve treatment outcomes 
and minimize unnecessary healthcare expenditures. 
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CHAPTER 4: METHODS 
4.1 DESIGN 
A population-based retrospective cross-sectional study was completed using Ontario 
Mental Health Reporting System (OMHRS) data collected from all inpatient psychiatric units in 
Ontario, Canada from January 1st, 2006 to December 31st, 2016.  
4.2 DATA 
A retrospective analysis of the OMHRS data was conducted. OMHRS is a central 
reporting system mandated by CIHI for all inpatient psychiatric units across Ontario. It includes 
comprehensive clinical information for each person admitted to inpatient mental health services 
from October 2005, until present. Facilities submit data to OMHRS in an encrypted format on a 
quarterly basis (75). CIHI is then responsible for assessing the data quality, producing quarterly 
reports summarizing the organizations’ data, and sharing anonymized data with researchers (75). 
Logic checks on the data are conducted to assess quality, validity, and consistency; data that does 
not meet standard is rejected and returned to the submitting organization so that errors be can 
fixed (75). The University of Waterloo has a data agreement with CIHI which permits the use of 
OHMRS data for research purposes.  
Data from inpatient psychiatry that is submitted to OMHRS is based on clinical 
assessments of inpatients that is captured using the Resident Assessment Instrument – Mental 
Health (RAI-MH). The RAI-MH is a comprehensive assessment tool composed of over 400 
items. Information captured using the RAI-MH is used to inform care planning, conduct outcome 
measurement, measure quality of care, and determine resource allocation for individuals 
receiving inpatient mental health care (76). An interdisciplinary team of clinical staff overseeing 
the care of individuals admitted to inpatient psychiatry complete the RAI-MH. The assessment is 
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completed using information collected from the admitted individual and from other key 
informants including family members, first responders, and other clinical staff, such as nurses, 
social workers, occupational therapists, and physicians (77). The assessment is completed at 
admission and discharge, as well as, every 90-days for long stay patients5. Extensive assessment 
of the reliability, validity, quality and applications of the data has been published (76,78-80).  
4.3 ETHICS 
Ethics approval was given by the Office of Research Ethics at the University of Waterloo 
on April 10th, 2018 (ORE #22962). This research was conducted under a broader research project 
titled, “Cannabis Legalization and Mental Health Outcomes Monitoring Systems,” led by Dr. 
Chris Perlman.  
4.4 SAMPLE 
The study sample was drawn from OMHRS data stored by CIHI. CIHI and the University 
of Waterloo have a data-sharing contract permitting the use of anonymized data for research 
purposes. Data included all RAI-MH assessments across all inpatient psychiatric units in 
Ontario, Canada from January 1st, 2006 to December 31st. 2016. The first available admission 
(index admission) for each inpatient in OMHRS was used. 
4.5 VARIABLES 
The variables considered for analysis are described below. Each is outlined further in 
Appendix A.   
 
 
                                                 
5 Long-stay patients are defined as patients staying for 3 or more days. A shorter assessment is 
completed for individuals admitted for less than 3 days. 
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4.5.1 Dependent Variables 
1) Past 30-day cannabis use: Measured on the RAI-MH in a section capturing substance use 
and excessive behaviours. Cannabis use is coded as: never of more than 1 year ago, within 
the last year, within the last 3 months, within the last month, within the last 7 days, and 
within the last 3 days. Past 30-day cannabis use was operationalized as a binary variable with 
presence indicating use in the past month and absence indicating no use in the past month. 
This dichotomization is commonly reported in the literature (81,82) and has been recognized 
as a potential indicator of more frequent/persistent use. For instance, criteria from the 
European Drug Monitoring Centre for Drugs and Drug Addiction use the past month cut off 
to indicate a current cannabis user, with past 30-day cannabis use defined as use within the 
past year but not in the past month, and experimental users to indicate lifetime users with no 
use in the past year (83).  
2) Readmissions: Defined as having an admission to a psychiatric unit 30-days following an 
index discharge. This was calculated by subtracting the admission date of a second admission 
from the index discharge date. The outcome was dichotomized as having a 30-day 
readmission, or not having a 30-day readmission. Individuals whose reason for an index 
discharge was coded as “transfer to another psychiatric hospital” or whose living 
arrangement at discharge was another mental health residence, a psychiatric hospital, a long-
term care facility (nursing home), a rehabilitation hospital/unit, a hospice facility/palliative 
care unit, or an acute care hospital were not coded as having a 30-day readmission. 
4.5.2 Independent Variables  
A different group of variables were analyzed for each research question (Table 2). 
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Table 2. Independent variables analyzed for each research question 
RESEARCH 
QUESTION 
VARIABLES ANALYZED 
Question 1 Sex 
Age 
Mental health diagnosis (DSM IV/V) 
Question 2 Year 
Demographic 
Factors 
Sex 
Age 
Marital status 
Education level 
Indigenous origin 
Residential stability 
Lived alone 
Employment status 
Risk of unemployment/disrupted education 
Substance 
Use 
Past year substance use  
Past 30-day substance use  
Problematic alcohol use 
Smoking 
Misuse of medications 
Clinical 
Variables 
Mental health diagnosis (DSM IV/V) 
Reason for admission  
Inpatient status at admission  
Length of stay (LOS) 
Clinical 
Indicators 
Safety – harm to self, harm to others 
Social life – social relationships, interpersonal conflict, 
traumatic life events, criminal activity 
Financial hardship 
Autonomy –medication adherence history, psychiatric 
hospitalizations (past 2 years), psychiatric hospitalizations 
(lifetime) 
Health promotion – sleep disturbance, pain 
Symptoms and functioning – Positive Symptom Scale, Social 
Withdrawal Scale, Cognitive Performance Scale, Depressive 
Severity Index, Mania Scale, CAGE, Anxiety Scale 
Question 3 Demographic 
Factors 
Sex 
Age 
Marital status  
Residential stability 
Lived alone 
Employment status 
Risk of unemployment/disrupted education 
Substance 
Use 
Past year substance use  
Past 30-day substance use  
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Problematic alcohol use 
Smoking 
Misuse of medications 
Clinical 
Variables 
Mental health diagnosis (DSM IV/V) 
LOS 
Contact with community mental health (past year) 
Clinical 
Indicators 
Safety – harm to self, harm to others 
Social life – social relationships, interpersonal conflict, 
traumatic life events, criminal activity, support system for 
discharge 
Autonomy – medication adherence history, psychiatric 
hospitalizations (past 2 years), psychiatric hospitalizations 
(lifetime) 
Health promotion – sleep disturbance, pain 
Symptoms and functioning – Positive Symptom Scale, Social 
Withdrawal Scale, Cognitive Performance Scale, Depressive 
Severity Index, Mania Scale, CAGE, Anxiety Scale 
4.5.2.1 Demographic Factors (Block 1): 
1. Sex: Coded as female, male or other. Dichotomized as male or non-male.    
2. Age: Calculated using the year of the index admission minus the year of birth (month and day 
of birth were not available for privacy reasons, resulting in an approximate age). Ordinal 
variable operationalized into 7 categories: <18, 18 to 24, 25 to 34, 35 to 44, 45 to 54, 55 to 
64, and 65 and older.  
3. Marital status: Coded as never married, married, partner/significant other, widowed, 
separated, or divorced. Operationalized as a categorical variable with 3 levels: never married; 
married/partner/significant other; and widowed/separated/divorced.  
4. Education level: Coded as no schooling, 8 grades or less, 9 to 11 grades, high school, 
technical or trade school, some college/university, diploma/bachelor’s degree, graduate 
degree, or unknown. Operationalized as an ordinal variable with 3 categories: less than high 
school, high school, and greater than high school.  
5. Indigenous origin: Binary variable (yes/no) answered to the statement “Person’s origin is 
Inuit, Métis or First Nations.” 
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6. Residential stability: Binary variable (yes/no) answered to the statement “Prior to admission, 
most recent residence was temporary (e.g. shelter).”  
7. Lived alone: This is based on an item assessing living arrangements, coded as lives alone, 
lives with spouse only, lives with spouse and other(s), lives with child(ren) (but not 
spouse/partner), lives with other(s) (not spouse or child(ren)), or lives in group setting with 
non-relative(s). Operationalized as a binary variable: lives alone or does not live alone. 
8. Employment status: Current employment status coded as: employed, unemployed but seeking 
employment, unemployed and not seeking employment, other, or unknown. Operationalized 
as a binary variable: employed or not employed. 
9. Risk of unemployment/disrupted education: Coded as yes, no, or not applicable to: increase 
in lateness or absenteeism over the last 6 months, poor productivity of disruptiveness at 
work/school, expresses intent to quit work/school, and persistent unemployment or 
fluctuating work history over the last 2 years. Operationalized as a binary variable as: at risk 
or not at risk/not applicable. A person was identified as being at risk if they were coded as 
‘yes’ to any of the above questions. 
4.5.2.2 Substance Use (Block 2): 
1. Past year substance use: Substances captured (in addition to cannabis) include inhalants 
(e.g., glue, gasoline, paint thinners, solvents), hallucinogens (e.g., phencyclidine or “angel 
dust,” LSD or “acid,” “magic mushrooms,” or ecstasy), cocaine and crack, stimulants (e.g., 
amphetamines such as “uppers,” “speed,” methamphetamine), and opiates (e.g., heroin). 
Coded as: used never or more than 1 year ago, within the last year, within the last 3 months, 
within the last month, within the last 7 days or within the last 3 days. Past year substance use 
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was defined as use of any of the above substances in the past year and was operationalized 
as a binary variable: used within the past year or did not use within the past year.  
2. Past 30-day substance use: Includes measures on the same substances considered for past 
year substance use. Past 30-day substance use was defined as use of any of the same 
substances in the past month and was operationalized as a binary variable: recently used or 
did not recently use. 
3. Problematic alcohol use: Ordinal variable with responses: none, 1, 2 to 4, or 5 or more to 
the question, “Number of drinks in any single sitting episode in the last 14 days.” 
Operationalized as less than 5 drinks or, 5 or more drinks. This cut off was chosen as 
consuming 5 or more drinks in a single setting is commonly considered problematic 
drinking.  
4. Smoking: Ordinal variable measuring daily smoking or chewing tobacco use. Ordinal 
variable coded as: no, not in the last 3 days but is a daily smoker, or yes. Dichotomized as a 
binary variable: not a daily smoker and either a daily smoker/usually a daily smoker. 
5. Misuse of medications: Measures the intentional misuse of prescription or over-the-counter 
medication in the last 3 months. Defined as the use of medication for a purpose other than 
intended. Operationalized as a binary variable (yes/no) to, “Use of medication for a purpose 
other than intended in the past 3 months.” 
4.5.2.3 Clinical Variables (Block 3): 
1. Mental health diagnosis: Captured with DSM codes recorded within the RAI-MH 
assessment. The DSM diagnoses are provided by a psychiatrist overseeing the care of the 
person at the time of assessment. DSM-IV codes were used in assessments from 2005 to 
2015 and were replaced with DSM-V codes in the 2016 assessments. Codes were 
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crosswalked to allow for continuity of data, with DSM V being coded into DSM-IV 
categories (Appendix B). Primary, secondary, and tertiary diagnosis were considered. 
Discharge diagnoses were used (rather than diagnosis at admission) as admissions diagnostic 
codes are often provisional. All diagnostic categories that represented less than 5% of the 
study population were combined and labelled as ‘other’. Diagnostic groups that were 
combined into the other category included: neurodevelopmental disorders; mental disorders 
due to general medical conditions; somatoform disorders; factitious disorders; dissociative 
disorders; sexual and gender identity disorders; eating disorders; sleep-wake disorders; 
disruptive, impulse-control and conduct disorders; adjustment disorders; obsessive-
compulsive and related disorders; trauma- and stressor-related disorders; elimination 
disorders; sexual dysfunction; paraphilic disorders; other mental disorders; and medication-
induced movement disorders and other adverse effects of medication. The 7 diagnostic 
groups that were analyzed for this research were: neurocognitive disorders, substance-related 
and addictive disorders, schizophrenia spectrum and other psychotic disorders, mood 
disorders (including bipolar and related disorders, and depressive disorders), anxiety 
disorders, personality disorders, and other disorders.  
2. Reason for admission: Binary variable (yes/no) answered to each of the following: threat or 
danger to self; threat or danger to others; inability to care for self due to mental illness; 
problem with addiction/dependency; specific psychiatric symptoms (e.g., depression, 
hallucinations, medication side effects); involvement with criminal justice system, forensic 
admission; other; or forensic assessment. Multiple reasons for admission could be present. 
Each reason for admission was assessed separately. 
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3. Inpatient status at admission: Nominal variable captured as: application for psychiatric 
assessment (excludes forensics), voluntary, informal, involuntary, or forensic (including 
forensic assessment, unfit to stand trial, and not criminally responsible). 
4. Past-year contact with community mental health: Measures the time since last contact with a 
community mental health agency or mental health professional (e.g. psychiatrist, social 
worker) in the last year. Ordinal variable operationalized into 3 categories: no contact in the 
last year, contact 31 days or more ago, contact within 30 days or less. 
5. Length of stay (LOS): Continuous variable measured by taking the difference between the 
date of admission and the date of discharge for the index admission. Categorized into 5 
levels: 3 to 14 days, 15 to 30 days, 31 to 60 days, 61 to 90 days, or greater than 90 days.  
4.5.2.4 Clinical Indicators: 
Items from the RAI-MH can be combined to form a number of clinical and risk indicators. 
These scales and items are used to assess safety, social life, financial hardship, autonomy, and 
health promotion. They can all be used to measure strengths and needs of an individual and 
therefore are used for care planning. In addition to these risk scales, items taken directly from the 
RAI-MH were used to evaluate clinical status by cannabis use status. Each item and scale is 
discussed further in Appendix A.  
1. Safety (Block 4): 
a. Harm to Others (RHO): Evaluated using 2items:  
i. History of violence: Includes measures of 4 items: expressing violence 
towards others, intimidation of others including threatened violence, violent 
ideation, and history of sexual violence or assault as the perpetrator. The first 
3 items are assessed with 6 different levels: never, more than 1 year ago, 31 
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days to 1 year ago, 8 to 30 days ago, 4 to 7 days ago, or in the last 3 days. This 
variable dichotomized as having a history (yes to any of the 4 items; 1), or not 
(0).  
ii. Aggressive Behaviour Scale (ABS): Assessment of verbal abuse, physical 
abuse, socially inappropriate/disruptive behaviours, and resistance to care. 
This scale ranges from 0 to 12 with higher scores indicating greater levels of 
aggression. This variable was dichotomized as having a score of 2 or less 
(absence; 0), or greater than 2 (presence; 1). This scale has been tested for 
reliability and validity (84).  
b. Self-Harm: Evaluated with 2 different items. These items were combined to create a 
dichotomous variable. Presence of self-harm was identified as having any history of 
either a suicide attempt or self-injury/behaviour. 
i. History of suicide attempt: Categorical variable with 3 levels: No suicide 
attempt history, history of hurting oneself but not with intent to kill self, intent 
of self-injury was to kill oneself. 
ii. History of self-injury/behaviour: Measured with 6 different levels assessing 
whether the most recent self-injurious attempt was: never, more than 1 year 
ago, 31 days to 1 year ago, 8 to 30 days ago, 4 to 7 days ago, or in the last 3 
days.  
2. Social Life (Block 5):  
a. Social relationships: Assessed using 2 items: 
i. Social isolation: Measured using 5 items: reports having no confidant 
(dichotomized: yes or no), participation in social activities of long-standing 
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interest (dichotomized: occurred within the past month, occurred greater than 
a month ago), withdrawal from activities of interest or from long-standing 
social relations (dichotomized: indicated in the past 3 days, not indicated in 
the past 3 days), reduced social interaction (dichotomized: indicated in the 
past 3 days, not indicated in the past 3 days), telephone or email contact with 
long-standing social relation/family member (dichotomized: occurred within 
the past month, occurred greater than a month ago). Social isolation was 
identified as present if an individual had no confidant and presence of one of 
the other 4 variables.  
ii. Dysfunction: Operationalized as a dichotomous variable and is determined to 
be present if an individual reports any one of the following: a belief that 
relationships with immediate family members is disturbed or dysfunctional 
(dichotomized: belief not present, or either the person believes, 
family/friends/others believe, or both the person and family/friends/others 
believe), family/close friends report feeling overwhelmed by person’s illness 
(dichotomized: yes or no), and conflict-laden or severed relationship, 
including divorce (dichotomized: history or no history).  
b. Support systems for discharge: Operationalized as a dichotomous variable; coded as 
present if there is no individual available to help with activities of daily 
living/independent activities of daily living, child care, crisis support, supervision of 
safety post-discharge, if an individual is homeless following discharge, or who do not 
have an individual who views their discharge into the community as positive. 
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c. Interpersonal conflict: Operationalized as a dichotomous variable. Present if there is 
any of the following: belief that relationship(s) with immediate family members are 
disturbed or dysfunctional, reports of having no confidant, family/close friends report 
feeling overwhelmed by person’s illness, is persistently hostile towards or critical of 
family/friends, is persistently hostile of others or staff, family/friends are persistently 
hostile towards or critical of person, staff reports persistent frustration in dealing with 
person, or if family/friends require unusual amounts of facility staff time. 
d. Traumatic life events: Categorical variable with 3 levels. Present if there is concerns 
for immediate safety based on the presence of abuse in the past 7 days or concerns for 
personal safety, need to reduce the impact of prior traumatic life events including the 
presence of one of: serious accident or physical impairment; death of a close family 
member or friend; lived in a war zone or an area of violent conflict; witness to a 
severe accident, a disaster, an act of terrorism or violence, or abuse; victim of crime, 
victim of sexual assault or abuse; victim of physical assault or abuse; victim of 
emption assault or if there is past traumatic life events, and they state that this event 
has caused an intense sense of horror or fear.  
e. Criminal activity: Operationalized as a dichotomous variable. Present if there is a past 
year history of violent or nonviolent criminal behaviour where there was police 
intervention. 
3. Financial Hardship and Autonomy (Block 6): 
a. Financial hardship: Operationalized as a dichotomous variable. Present if someone 
has a lifetime history of major loss of income or serious economic hardship due to 
poverty. 
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b. Medication management: Operationalized as a dichotomous variable. Present if there 
is need for some sort of assistance to manage medications (e.g., to remember to take 
medications, opening bottles, taking correct drug dosages, giving injections, applying 
ointments). 
c. Medication adherence: Measures level of adherence to prescribed medications the 
month prior to admission. Recorded as: always adherent, adherent 80% or more of 
time, adherent 80% of time including failure to purchase prescribed medication, no 
medication prescribed, and unknown.  
d. Recent psychiatric admissions (past 2 years): Categorical variable: no recent 
admissions, 1 to 2 recent admissions, or 3 or more recent admissions. 
e. Lifetime psychiatric admissions: Categorical variable: no lifetime admissions, 1 to 3-
lifetime admissions, 4 to 5-lifetime admissions, or 6 or more recent admissions. 
f. Independence: Measured using the Instrumental Activities of Daily Living (IADL) 
Capacity Scale. Includes assessment of ability to conduct meal preparation, ordinary 
housework, ability to manage finances and medications, phone use, shopping, and 
transportation. Scores range from 0 to 42 with higher scores indicating lower 
capacity. Categorized into 3 levels based on the additive score: 0 to 2, 3 to 5, 6 or 
higher. 
4. Health Promotion (Block 7): 
a. Sleep disturbance: Assesses whether an individual is experiencing current sleep 
problems based on reported sleep problems (e.g., difficulty falling asleep, restless or 
non-restful sleep, interrupted sleep, too much sleep) in the past 3 days. Dichotomized 
as sleep disturbances are present or absent. 
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b. Pain: An ordinal variable that measures both the frequency and intensity of pain. 
Operationalized with 3 levels: expressing no pain, moderate pain, or severe pain. 
5. Symptom Severity (Block 8): 
a. Positive Symptoms: Measured with the Positive Symptom Scale (PSS) – short. This 
scale assesses hallucinations, command hallucinations, delusions, and abnormal 
thought processes. Scores range from 0 to 12, with higher scores indicating higher 
levels of positive symptoms. Dichotomized as presence (score >2) or absence (score 
≤2). This scale has been found to have good internal consistency for the inpatient 
population (67).   
b. Social Withdrawal: Measured with the Social Withdrawal Scale (SWS). Includes 
assessments of motivation levels, reduced interaction, decreased energy, expression 
of flat or blunted affect, anhedonia, and loss of interest. Scores range from 0 to 6 with 
higher scores indicating greater social withdrawal. This scale has been tested for 
reliability and validity, and has been found to have strong internal consistency (85). 
Categorized into 4 levels based on summed scores: no social withdrawal, score of 1 to 
2, scores of 3 to 5, and score of 6. 
c. Cognitive Performance: Measured with the Cognitive Performance Scale (CPS). 
Includes an assessment of daily decision making, short-term memory, ability to 
express oneself, and self-performance of eating. Scores range from 0 to 6 with higher 
scores indicating greater level of impairment. Validity of this scale has been assessed 
(78). Dichotomized as presence (score >2), or absence (scores ≤2). 
d. Depressive Symptoms: Measured using the Depression Severity Index (DSI) and is 
based on the presence of sad/pained facial expressions, negative statements, self-
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deprecation, guilt/shame and hopelessness. Scores range from 0 to 15 with higher 
scores indicating higher levels of depressive symptoms. Dichotomized as absence 
(score <3) and presence (score ≥3). This scale has been tested for reliability and 
validity (86). 
e. Mania: Measured based on indicators including inflated self-worth, hyperarousal, 
irritability, increased sociability, pressured speech, labile effects, and sleep problems 
due to hypomania. Scores range from 0 to 20 with higher scores indicating more 
symptoms of mania.  Categorized with 4 levels based on summed scores: no 
symptoms of mania, scores of 1 to 3, scores of 4 to 8, and scores greater than 8. No 
current literature has assessed the reliability and validity of this scale. However, 
internal consistency was assessed with the current data (Cronbach’s alpha=0.69).  
f. Problem with addiction: Assessed using the CAGE scale and indicates whether there 
may be a potential problem with substance addiction. Indicators include the need to 
cut down on substance use, angered by criticisms from others, expression of guilt 
about substance use, and drinking or use of other substances in the morning. Scores 
are summed and range from 0 to 4. This variable is dichotomized as scores less than 2 
and 2 or more indicating a potential problem with substance addiction. There is 
limited research on the reliability of the CAGE as an embedded scale in the RAI-MH. 
Therefore, internal consistency was evaluated based on the current sample, with 
results supporting good internal consistency (Cronbach’s alpha=0.89). 
g. Anxiety: Used to assess levels of anxiety. Indicators of anxiety include presence of 
anxious complaints, fears/phobias, obsessive thoughts, compulsive behaviour, 
intrusive thoughts/flashbacks, and episodes of panic. Each indicator is measured as 
40 
 
indicator not exhibited in the last 3 days, indicator not exhibited in the last 3 days but 
is reported to be present, indicator exhibited on 1 to 2 of the last 3 days, indicator 
exhibited daily in the last 3 days. Dichotomized as indicator not exhibited in the last 3 
days or indicator exhibited in the 3 days (not exhibited but reported to be present, 1 to 
2 of the last 3 days, daily in the last 3 days). Score across all indicators are summed. 
Higher scores indicate greater levels of anxiety. No literature has assessed this scale. 
However, internal consistency was assessed with the current data (Cronbach’s 
alpha=0.68). 
4.6 ANALYSES 
All analyses were conducted using Statistical Analysis Software (SAS) 9.4.  
4.7 STATISTICAL METHODS 
Research Question 1: Trends in cannabis use 
Time-trend analyses were conducted to explore trends in the proportion of persons 
admitted to inpatient psychiatry reporting past 30-day cannabis in Ontario, Canada from 2006 to 
2016.  Prevalence was also calculated over time for age, sex, and DSM diagnosis. This was done 
to determine whether certain populations disproportionately represented past 30-day cannabis 
users and whether changes in rates of use were concentrated among individuals with particular 
demographic and clinical characteristics.  
Research Question 2: Characteristics of cannabis use 
Logistic regression was used to examine characteristics associated with past 30-day 
cannabis use among individuals in inpatient psychiatry. Bivariate analyses were first conducted 
to identify demographic and clinical factors significantly associated with past 30-day cannabis 
use (p<0.0001). Variables that were not significant at the bivariate level were removed. Variables 
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found to be statistically significant were removed if there was less than a 5% difference in the 
prevalence of past 30-day cannabis users between any two levels of that variable (e.g., if the 
difference in prevalence of cannabis use between males and non-males was less than 5%, sex 
would be removed from the model). The remaining variables were considered for the 
multivariate model. Due to the large number of variables being included in the analysis, block 
modelling was carried out with all of the variables that were significant at the bivariate level. 
Blocks are outlined in Appendix A. After each block was modelled independently, all significant 
variables from each block were included in a final model. Non-significant variables were 
manually removed and interactions between sex and age, and sex and diagnostic categories were 
examined. Year of admission was also evaluated in the final model, adjusting for all other 
variables found to be significant. 
Research Question 3: 30-day readmissions by cannabis use status 
For this analysis, individuals were not counted as being readmitted if they were 
transferred to another mental health facility, psychiatric hospital, long-term care, a rehabilitation 
unit, palliative care, or acute hospital. This was done to avoid miscounting a transfer as a 
readmission. Individuals who died in hospital at index admissions were excluded. Once the study 
sample was reduced, 30-day readmission rates were analyzed to determine whether rates differed 
among past 30-day cannabis users and non-recent users. First, a bivariate analysis was conducted 
to determine whether past 30-day cannabis use was significantly associated 30-day readmissions 
at the bivariate level. Bivariate modelling was then carried forward to identify other variables 
significantly associated with 30-day readmissions among the general inpatient psychiatric 
population. Non-significant variables (p<0.0001) were removed and block modelling was carried 
out similar to the previous question. Past 30-day cannabis was added into the final model to 
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determine whether it remained significantly associated with 30-day readmissions after 
controlling for all other significant variables. Potential interactions with past 30-day cannabis use 
were identified by examining readmission rates among past 30-day cannabis users relative to 
non-recent users for demographic and clinical characteristics. Cross tabulations that showed 
considerable difference in the prevalence of readmissions between each group were examined as 
interactions in the multivariate model. 
Two separate models were then created to identify variables associated with readmissions 
among cannabis users and non-users. The same process was repeated, identifying variables 
associated with readmissions in past 30-day cannabis users, testing individual blocks, and adding 
blocks together to generate a final model. This process was again repeated among the cohort of 
non-cannabis users.  
4.9 EXCLUSION CRITERIA 
Short-stay patients (admissions <3 days) were excluded as they are not assessed with the 
full RAI-MH assessment. 
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CHAPTER 5: RESULTS 
5. 1 PREVALENCE OF CANNABIS USE BY POPULATION CHARACTERISTICS 
5.1.1 Prevalence of past 30-day cannabis use 
Across all study years (2006 to 2006), 18.9% (n=30330) of individuals admitted to 
inpatient psychiatry reported past 30-day cannabis use, where 81.1% (n=130002) reported no 
past 30-day cannabis use. More specifically, 75.2% of all inpatients had no lifetime or past year 
cannabis use, 3.6% used within the past year, 2.3% used in the past 3 months, 5% used in the 
past month, 6.7% used in the past 7 days, and 7.2% used in the past 3 days. 
Across the study period, the prevalence of males and non-males was approximately 
(50.8% versus 49.2%, respectively) (Table 3). However, cannabis use was higher among males 
at 24.4%, compared to 13.2% among non-males. The greatest prevalence of past 30-day cannabis 
use was among 18 to 24-year olds (42%), followed by those younger than 18-years of age 
(36.8%), 25 to 34-year olds (30.3%), 35 to 44-year olds (18.6%), 45 to 54-year olds (12.7%), 55 
to 64-year olds (5.9%), and finally, 65 and older (0.8%). The prevalence of cannabis use was 
higher among those who were never married (28.2%), compared to those who were married or 
had a partner/significant other (10.4%), or who were widowed, separated or divorced (11.1%). 
Half of the study population had greater than a high school education, 24.4% had less than a high 
school education and 25% had a high school level education. Having a higher level of education 
was associated with lower prevalence of cannabis use; 23% of individuals with less than a high 
school education reported past 30-day cannabis use relative to 21.1% of individuals with a high 
school education, and 15.9% of individuals with greater than a high school education. The 
majority of the study population did not identify as being of Indigenous origin (97%). However, 
the prevalence of cannabis use was higher among those of Indigenous origin (36.3% relative to 
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18.4%). Nearly one quarter of the study population stated that their most recent residence was 
temporary with the prevalence of cannabis use being similar between those with and without 
residential instability (19.9% and 18.6%, respectively). The majority of the study population did 
not live alone at the time of admission (71.2%), and there was approximately equal reported past 
30-day cannabis use among those who did and did not live alone (17.8% and 19.4%, 
respectively). There was greater prevalence of cannabis use among those who were at risk of 
unemployment or disrupted education (27.6%) relative to those who were not at risk (16%).  
Table 3. Prevalence of past 30-day cannabis use among the inpatient psychiatric population 
by individual demographic characteristics 
CHARACTERISTICS PROPORTION 
REPORTING 
PAST 30-DAY 
CANNABIS 
N (%) 
TOTAL  
STUDY 
POPULATION 
N (%) 
Sex Male  19916 (24.4) 81481 (50.8) 
Non-male 10414 (13.2) 76651 (49.2) 
Age <18 1269 (36.8) 3452 (2.5) 
18-24 10120 (42.0) 24073 (15.0) 
25-34 8163 (30.3) 26904 (16.8) 
35-44 5338 (18.6) 28637 (17.9) 
45-54 4034 (12.7) 31766 (19.8) 
55-64 1220 (5.9) 20636 (12.9) 
65+ 186 (0.8) 24864 (15.5) 
Marital status Never married 21282 (28.2) 75506 (47.1) 
Married/Partner/Significant other 5352 (10.4) 51545 (32.2) 
Widowed/Separated/Divorced 3696 (11.1) 33281 (20.8) 
Education level < High school 8984 (23.0) 39132 (24.4) 
High school 8478 (21.2) 40070 (25.0) 
> High school 12868 (15.9) 81130 (50.6) 
Indigenous origin Yes 1762 (36.3) 4849 (3.0) 
No 28568 (18.4) 155483 (97.0) 
Residential 
stability 
Temporary residence 7997 (19.9) * 40130 (25.0) 
Non-temporary residence 22333 (18.6) 120202 (75.0) 
Lived alone Lived alone 8201 (17.8) 46151 (28.8) 
Did not live alone 22129 (19.4) 114181 (71.2) 
Employment status Employed 9023 (21.0) 43068 (26.9) 
Not employed 21307 (18.2) 117264 (73.0) 
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Risk of 
unemployment/ 
disrupted 
education 
At risk 11160 (27.6) 40447 (25.2) 
Not at risk 19170 (16.0) 119885 (74.8) 
*Bolded variables indicate less than a 5% difference in the prevalence of cannabis users among all levels of that 
variable. Regardless of their significance at the bivariate level, these variables were removed for the logistic 
regression modelling process for Research Question 2. 
 
5.1.2 Diagnostic characteristics of study population and prevalence of past 30-day cannabis 
use  
Of the seven diagnostic groups, individuals with a primary, secondary, or tertiary 
diagnosis of a substance-related and addictive disorder had the highest prevalence of reported 
past 30-day cannabis users (38.3%). Individuals with personality disorders had the second 
highest prevalence of reported past 30-day cannabis users (24%), followed by schizophrenia and 
other psychotic disorders (20.3%), other disorders (17.4%), mood disorders (17.1%), anxiety 
disorders (16.5%), and neurocognitive disorders (1.9%) (Table 4).  
Table 4. Prevalence of past 30-day cannabis use in the inpatient psychiatric population by 
mental health diagnosis 
DIAGNOSTIC GROUP PROPORTION 
REPORTING 
PAST 30-DAY 
CANNABIS 
N (%) 
TOTAL 
STUDY 
POPULATION 
N (%) 
Neurocognitive disorders 252 (1.9) 13578 (8.5) 
Substance-related and addictive disorders 16840 (38.3) 44016 (27.5) 
Schizophrenia and other psychotic disorders 8631 (20.3) 42622 (26.6) 
Mood disorders 14488 (17.1) 84547 (52.7) 
Anxiety disorders 3830 (16.5) 23299 (14.5) 
Personality disorders 3210 (24.0) 13376 (8.3) 
Other disorders* 3766 (17.4) 21615 (13.5) 
*Diagnostic categories were only considered for the analysis if at least 5% of the inpatient population had a 
primary, secondary, or tertiary diagnosis under the category. Those that represented less than 5% of the inpatient 
population were amalgamated into the ‘other’ category.  
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5.1.3 Substance use characteristics of study population and prevalence of past 30-day 
cannabis use  
Among the inpatient population, 16.9% stated they had past year use of inhalants, 
hallucinogens, cocaine or crack, stimulants, or opiates, with 11.6% having used these substances 
in the prior 30-days. Among those using these substances in the prior year, 47.4% also reported 
past 30-day cannabis use, where 53.1% of individuals who used these substances in the past 
month reported past 30-day cannabis use. Those who used hallucinogens either in the past year 
or past month were most likely to also have recently used cannabis (65.5% and 79.4%, 
respectively). Within the study population, 38.7% reported tobacco use, of which 33.8% also 
reported past 30-day cannabis use. However, only 9.6% of non-smokers reported past 30-day 
cannabis use. A greater proportion of individuals with “problematic” drinking patterns reported 
past 30-day cannabis use (35.1%), relative to individuals who consumed less alcohol (15.9%). 
Finally, a greater proportion (26.9%) of individuals who stated that they had intentionally 
misused medication reported past 30-day cannabis use relative to those who did not report the 
intentional misuse of medication (17.7%) (Table 5). 
Table 5. Prevalence of past 30-day cannabis use in the inpatient psychiatric population by 
other substance use behaviours 
SUBSTANCE USE BEHAVIOURS  PROPORTION 
REPORTING 
PAST 30-DAY 
CANNABIS 
USE 
N (%) 
TOTAL 
STUDY 
POPULATION 
N (%) 
Past year 
substance 
use 
Any substance use 12823 (47.4) 27032 (16.9) 
Inhalants 737 (45.1) 1634 (1) 
Hallucinogens 3394 (65.5) 5342 (3.3) 
Cocaine and crack 9107(53.4) 17054 (10.6) 
Stimulants 3699 (56.0) 6601 (4.1) 
Opiates 5061 (42.9) 11802 (7.4) 
Cannabis 30330 (76.3) 39760 (24.8) 
Any past 30-day substance use 9855 (53.1) 19570 (11.6) 
Inhalants 453 (58.0) 781 (0.5) 
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Past 30-day 
substance 
use 
Hallucinogens 1687 (79.4) 2126 (1.3) 
Cocaine and crack 6345 (60.9) 10412 (6.5) 
Stimulants 2429 (65.5) 3710 (2.3) 
Opiates 3776 (46.1) 8190 (5.1) 
Problematic 
alcohol use 
Yes 8859 (35.1) 25232 (15.7) 
No 21471 (15.9) 135100 (84.3) 
Smoking Yes 20924 (33.8) 62000 (38.7) 
No 9406 (9.6) 98332 (61.3) 
Misuse of 
medications 
Yes 5720 (26.9) 21256 (13.3) 
No 24610 (17.7) 139076 (86.7) 
5.1.4 Clinical characteristics of study population and prevalence of past 30-day cannabis 
use 
The greatest prevalence of past 30-day cannabis use was reported in those who were 
admitted to inpatient psychiatry for problems with addiction (39%), involvement with the 
criminal justice system (23.6%), and for being a threat to others (15.8%). There was a 
relationship between past 30-day cannabis use and LOS (x2=1598.9, p<0.0001) with shortest 
stays (3 to 14 days) having the greatest proportion of past 30-day cannabis users (22.1%) relative 
to those with the longest stays (>90 days; 6.5%). The prevalence of past 30-day cannabis use was 
similar among those who visited community mental health in the past 30 days and those who had 
not. There was a greater prevalence of past 30-day cannabis use among those experiencing 
financial hardship (25.9%) relative to those not experiencing hardship (18.8%). Medication 
adherence was also associated with past 30-day cannabis use, with a higher proportion of recent 
use among those who were less adherent; 14.2% of individuals who were always adherent to 
prescribed medication reported past 30-day cannabis use, compared to 17.3% of those who were 
adherent at least 80% of the time, 22.5% of those who were adherent less than 80% of the time 
and 33.3% of those with no medication history. There was little difference in prevalence of 
cannabis use when looking at recent psychiatric hospitalization history. However, increasing 
number of lifetime admissions was associated with lower prevalence of reported past 30-day 
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cannabis users (e.g., 18.6% among those with no lifetime admission versus 14.1% of those with 
6 or more admissions). There was decreasing prevalence of reported past 30-day cannabis use as 
an individual’s dependence level increased (Table 6).   
Table 6. Prevalence of past 30-day cannabis use among the inpatient psychiatric population 
by clinical characteristics 
CLINICAL CHARACTERISTICS PROPORTION 
REPORTING 
PAST 30-DAY 
CANNABIS 
USE 
 N (%) 
TOTAL 
STUDY 
POPULATION 
N (%) 
Reason for 
admission 
Threat to self 15511 (20.6) 75410 (47.0) 
Threat to others 6202 (21.3) 29190 (18.2) 
Inability to care 9166 (15.8) 58105 (36.2) 
Problem with addiction 16648 (39.0) 42740 (27.4) 
Specific psychiatric symptoms 21447 (18.6) 115513 (72.1) 
Involvement criminal justice system 1959 (23.6) 8307 (5.2) 
Other 874 (14.4) 6052 (14.4) 
Forensic assessment 167 (15.3) 1093 (0.7) 
Inpatient 
status at 
admission 
Application for psychiatric assessment 10121 (23.2) 43610 (27.2) 
Voluntary 7255 (18.4) 39413 (24.6) 
Informal 70 (5.2) 1346 (0.8) 
Involuntary 3549 (20.0) 17718 (11.1) 
Forensic 1982 (23.5) 8452 (5.3) 
LOS 3-14 days 14582 (22.1) 65848 (41.2) 
15-30 days 10449 (19.4) 54013 (33.8) 
31-60 days 4293 (15.3) 28074 (17.6) 
61-90 days 588 (10.3) 5730 (3.6) 
>90 days 403 (6.5) 6222 (3.9) 
Past year 
contact with 
community 
MH 
No contact 17423 (19.8) 87996 (54.9) 
Contact >30 days 4495 (19.7) 22843 (14.3) 
Contact <30 days 8412 (17.0) 49493 (30.9) 
Safety Harm to others History of violence 9107 (27.8) 32709 (20.4) 
Aggressive Behaviour 
Scale (>2) 
5220 (21.1) 24792 (15.5) 
Self-harm Yes 17177 (19.3) 89182 (55.6) 
No 13153 (18.5) 71150 (44.4) 
Social life Social 
relationships 
Social isolation 3631 (19.7) 18412 (11.5) 
Dysfunction 20289 (21.5) 94184 (58.7) 
Interpersonal conflict 19820 (20.8) 95167 (59.4) 
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Traumatic life 
events 
Current abuse 2909 (24.0) 12133 (7.6) 
Past traumatic event(s) 3573 (25.0) 14487 (9.0) 
No history 23848 (17.8) 133712 (83.4) 
Criminal activity 11745 (28.5) 41255 (25.7) 
No support systems for discharge  9258 (18.4) 50227 (31.3) 
Financial 
hardship 
Yes 6240 (25.9) 24125 (23.2) 
No 14989 (18.8) 79732 (76.8) 
Autonomy Medication 
management 
Independent 23108 (21.9) 105526 (65.8) 
Needs assistance 7222 (13.2) 54806 (34.2) 
Medication 
adherence 
history 
Always adherent 9571 (14.2) 67362 (42.0) 
Adherent >80% of time 5602 (17.3) 32347 (20.2) 
Adherent <80% of the 
time 
6492 (22.5) 28912 (18.0) 
No medication 5438 (33.2) 16404 (10.0) 
Unknown 3227 (21.1) 15307 (9.6) 
Number of 
psychiatric 
hospitalizations 
in prior 2 years 
0 23286 (18.6) 124931 (77.9) 
1-2 admissions 5896 (20.3) 29086 (18.1) 
3+ admissions 1166 (18.5) 6315 (3.9) 
Number of 
psychiatric 
hospitalizations 
in lifetime 
0 17725 (20.0) 88539 (55.2) 
1-3 admissions 9535 (18.7) 51000 (31.8) 
4-5 admissions 1642 (15.4) 10652 (6.6) 
6+ admissions 1428 (14.1) 10141 (6.3) 
Independence Lowest dependence 25279 (22.2) 113877 (71.0) 
Moderate dependence 1935 (17.9) 10820 (6.8) 
Greatest dependence 3116 (8.7) 35635 (22.2) 
 
5.1.5 Symptoms severity of study population and prevalence of past 30-day cannabis use  
Among those who with more severe positive symptoms on the PSS (scores >2), 20.6% 
were past 30-day cannabis users compared to 18.1% of those who did not trigger the PSS. An 
inverse relationship was found between past 30-day cannabis use status and social withdrawal 
severity; as withdrawal scores increased, the prevalence of past 30-day cannabis users decreased; 
21.5% of individuals who scored lowest on the SWS reported past 30-day cannabis use, relative 
to 14.9% who scored highest. The prevalence of past 30-day cannabis use did not differ between 
those with scores above and below 3 on the Depressive Severity Index. Higher prevalence of 
cannabis use was found among those with greater symptoms of mania (28.7%) relative to those 
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with no mania symptoms (15.5%). Those who scored higher on CAGE scale had greater past 30-
day cannabis use (31.7% relative to 14.1%). Finally, those who had higher anxiety scores, as 
measured by the Anxiety Scale, had roughly equal rates of past 30-day cannabis use to those who 
did not trigger the scale (Table 7).  
Table 7. Prevalence of past 30-day cannabis use among the inpatient psychiatric population 
by symptom severity  
SYMPTOM SCALE SCORE PROPORTION 
REPORTING 
PAST 30-DAY 
CANNABIS 
USE  
 N (%) 
TOTAL 
STUDY 
POPULATION 
N (%) 
Positive Symptom Scale 0-2: No or mild symptoms 19417 (18.1) 107383 (67.0) 
3+: More severe 
symptoms 
10913 (20.6) 52949 (33.0) 
Social Withdrawal Scale 0: No withdrawal 8028 (21.5) 37402 (23.3) 
1,2 9831 (20.4) 48255 (30.1) 
3,4,5 9539 (17.4) 54982 (34.3) 
6: Most severe withdrawal 2932 (14.9) 19693 (12.3) 
Cognitive Performance Scale 0-2: No or mild 
impairment 
29056 (20.1) 
 
144613 (90.2) 
 
3+: More severe 
impairment 
1274 (8.1) 15719 (9.8) 
Depressive Severity Index 0-2: No or mild 
depression 
12836 (19.0) 67438 (42.1) 
3+: More severe 
depression 
17494 (18.8) 92894 (57.9) 
Mania Scale 0: No mania symptoms 11293 (15.5) 73046 (45.5) 
1 7726 (18.6) 41577 (25.9) 
2 7300 (23.0) 31708 (19.8) 
3: Most severe symptoms 4011 (28.7) 14001 (8.7) 
CAGE 0-1: No potential problem 
with addiction 
17374 (14.1) 
 
123180 (78.8) 
 
2+: Potential problem 
with addiction 
12476 (37.7) 33085 (21.1) 
Anxiety Scale 0-2: No or mild anxiety 25034 (18.9) 132383 (82.6) 
3+: More severe anxiety 5296 (19.0) 27949 (17.4) 
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5.2 QUESTION 1: TRENDS IN CANNABIS USE 
5.2.1 General trend in proportion of inpatients reporting past 30-day cannabis use 
From 2006 to 2016, the number of individuals in inpatient psychiatry who reported past 
30-day cannabis use increased by approximately 10% from 15.4% in 2006 to 25.3% in 2016. 
This represents a 64% increase in overall prevalence (Table 8, Figure 1).  
Table 8. Prevalence of past 30-day cannabis use among the inpatient psychiatric population 
from 2006 to 2016 
YEAR PROPORTION 
REPORTING PAST 
30-DAY CANNABIS 
USE 
N (%) 
TOTAL STUDY 
POPULATION 
N 
2006 3214 (15.4) 20827 (13.0) 
2007 2727 (16.1) 16911 (10.6) 
2008 2565 (16.8) 15303 (9.5) 
2009 2493 (17.0) 14666 (9.2) 
2010 2502 (18.0) 13915 (8.7) 
2011 2607 (19.2) 13588 (8.5) 
2012 2551 (19.1) 13387 (8.4) 
2013 2723 (20.5) 13266 (8.3) 
2014 2923 (22.1) 13204 (8.2) 
2015 2810 (22.3) 12580 (7.9) 
2016 3215 (25.3) 12685 (7.9) 
Absolute change (%) 9.9  
Relative change (%) 64.3 
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Figure 1. Reported past 30-day cannabis use from 2006 to 2016 among the inpatient 
psychiatric population 
 
5.2.2 Trend in proportion of inpatients reporting past 30-day cannabis use by sex 
The prevalence of reported past 30-day cannabis use increased for both males and non-
males (Table 9). From 2006 to 2016 there was an 11.1% absolute change in reported cannabis 
among males (Figure 2), attributing to a 54.4% relative increase. In non-males, reported past 30-
day cannabis use increased by 8.5%, which is a relative increase of 82.5%. This suggests that 
males are more likely to report past 30-day cannabis use, but that non-males had a greater 
increase in use during the study period.  
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Table 9. Prevalence of past 30-day cannabis use among the inpatient psychiatric population 
from 2006 to 2016 stratified by sex categories 
 SEX 
YEAR MALE 
 N (%) 
NON-MALE 
N (%) 
2006  2162 (20.4) 1052 (10.3) 
2007 1806 (21.3) 921 (10.9) 
2008 1712 (22.6) 853 (11.1) 
2009 1655 (22.2) 838 (11.6) 
2010 1684 (23.5) 818 (12.1) 
2011 1737 (24.8) 870 (13.2) 
2012 1655 (24.4) 896 (13.5) 
2013 1734 (26.2) 989 (14.9) 
2014 1879 (27.7) 1044 (16.3) 
2015 1833 (28.1) 977 (16.1) 
2016 2059 (31.5) 1156 (18.8) 
Absolute change (%) 11.1 8.5 
Relative change (%) 54.4 82.5 
 
 
Figure 2. Reported past 30-day cannabis use from 2006 to 2016 stratified by sex categories 
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5.2.3 Trend in proportion of inpatients reporting past 30-day cannabis use by age 
Nearly all age groups had increases in past 30-day cannabis use from 2006 to 2016 
(Table 10, Figure 3). Inpatients less than 18 years, however, had a slight decrease in past 30-day 
cannabis use across the study period. Individuals age 65 and older had the largest percent 
increase at 467%, however, this was only an absolute increase of 1.5%. Individuals ages 18 to 24 
remained the greatest users throughout the entire study period with nearly half (48%) reporting 
past 30-day cannabis use in 2016.
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Table 10. Prevalence of reported past 30-day cannabis use among the inpatient psychiatric population from 2006 to 2016 
stratified by age categories 
 AGE 
YEAR <18 
N (%) 
18-24 
N (%) 
25-34 
N (%) 
35-44 
N (%) 
45-54 
N (%) 
55-64 
N (%) 
65+ 
N (%) 
2006 103 (36.0) 865 (36.2) 980 (26.8) 772 (16.5) 419 (8.5) 71 (2.9) ** 
2007 103 (34.6) 717 (36.8) 834 (27.8) 595 (16.4) 396 (11.0) 75 (3.7) 7 (0.3) 
2008 123 (39.2) 727 (38.3) 726 (27.9) 539 (17.9) 363 (11.3) 75 (4.0) 12 (0.5) 
2009 106 (40.2) 742 (40.0) 691 (28.5) 479 (17.6) 385 (12.1) 81 (4.2) 9 (0.4) 
2010 100 (39.2) 825 (41.9) 655 (29.3) 446 (18.4) 378 (12.9) 82 (4.3) 16 (0.7) 
2011 118 (39.9) 904 (43.6) 696 (31.3) 390 (17.0) 404 (14.3) 87 (5.0) 8 (0.4) 
2012 134 (36.6) 896 (41.4) 645 (29.7) 404 (19.0) 331 (12.5) 118 (6.6) 23 (1.1) 
2013 124 (36.4) 1038 (44.0) 640 (30.5) 399 (18.8) 356 (14.9) 139 (7.9) 27 (1.2) 
2014 130 (35.9) 1131 (45.4) 746 (34.8) 431 (22.2) 327 (13.9) 142 (8.1) 16 (0.7) 
2015 101 (32.3) 1021 (42.9) 750 (34.8) 453 (22.9) 321 (15.3) 161 (9.4) 31 (1.5) 
2016 127 (35.6) 1254 (48.3) 800 (36.7) 458 (25.1) 354 (16.8) 189 (11.7) 33(1.7) 
Absolute 
change (%) 
-0.4 12.1 9.9 8.6 8.3 8.9 1.5 
Relative 
change (%) 
-1.1 33.4 36.9 52.1 97.6 303.4 466.7 
**Results not reported due to a cell count of less than 5.  
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Figure 3. Reported past 30-day cannabis use from 2006 to 2016 stratified by age categories 
5.2.4 Trend in proportion of inpatients reporting past 30-day cannabis use by diagnostic 
group 
The prevalence of past 30-day cannabis use increased among all diagnostic categories 
with the prevalence almost doubling among those with schizophrenia and other psychotic 
disorders; in 2006 approximately 15.2% of individuals with a primary, secondary, or tertiary 
diagnosis of schizophrenia or other psychotic disorders reported past 30-day cannabis use, 
relative to 30.6% reporting use in 2016. Large increases were also seen among individuals with 
personality disorders and anxiety disorders, with a 97.1% relative increase for personality 
disorders, and an 87.8% increase for anxiety disorders. There was a 64.7% relative increase in 
use among those with neurocognitive disorders, however, this was only due to a 1.1% absolute 
increase in the number of past 30-day cannabis users.  
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Although the proportion of individuals reporting past 30-day cannabis use for all 
diagnostic groups from 2006 to 2016 increased, the absolute number of individuals reporting past 
30-day cannabis use for some diagnostic categories decreased (Table 11, Figure 4). Among those 
with neurocognitive disorders, anxiety disorders, personality disorders and disorders in the 
‘other’ category both the number and proportion of individuals reporting past 30-day cannabis 
use increased. However, for substance-related and addictive disorders, schizophrenia and other 
psychotic disorders, and mood disorders, the number of individuals reporting past 30-day 
cannabis use from 2006 to 2016 decreased while the actual proportion of individuals in each 
diagnostic group reporting past 30-day cannabis use increased.
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Table 11. Prevalence of reported past 30-day cannabis use among the inpatient psychiatric population from 2006 to 2016 
stratified by DSM diagnostic groups 
 DIAGNOSTIC GROUP 
YEAR Neurocognitive 
disorders 
N (%) 
Substance-
related and 
addictive 
disorders 
N (%) 
Schizophrenia 
and other 
psychotic 
disorders 
N (%) 
Mood 
disorders 
N (%) 
Anxiety 
disorders  
N (%) 
Personality 
disorders 
N (%) 
Other 
disorders 
N (%) 
2006 27 (1.7) 1857 (34.1) 1038 (15.2) 1443 (13.7) 277 (11.5) 355 (17.5) 347 (12.8) 
2007 25 (1.8) 1537 (33.3) 732 (15.6) 1259 (14.3) 242 (12.5) 284 (19.8) 300 (14.4) 
2008 22 (1.7) 1443 (35) 658 (16.5) 1260 (15.3) 265 (13.7) 303 (22.8) 266 (14.6) 
2009 18 (1.5) 1371 (34.3) 660 (17.0) 1186 (15.4) 323 (15.8) 293 (23.5) 307 (16.7) 
2010 23 (1.9) 1455 (37.3) 697 (19.7) 1234 (16.4) 299 (14.9) 264 (23.6) 322 (18.0) 
2011 17 (1.4) 1467 (38.2) 721 (20.7) 1283 (17.6) 359 (17.1) 294 (25.9) 329 (18.3) 
2012 17 (1.5) 1436 (39.4) 686 (20.1) 1288 (17.9) 370 (17.1) 236 (24.1) 313 (17.6) 
2013 30 (2.5) 1483 (41.2) 804 (23.9) 1325 (18.6) 382 (17.3) 258 (25.2)  326 (18.0) 
2014 27 (2.4) 1597 (43.2) 860 (26.3) 1434 (20.4) 447 (19.9) 269 (26.4) 388 (19.6) 
2015 18 (1.6) 1561 (43.3) 811 (26.6) 1354 (20.0) 455 (20.2) 293 (28.8) 353 (20.3) 
2016 28 (2.8) 1633 (46.0) 964 (30.6) 1422 (22.3) 411 (21.6) 361 (34.5) 515 (22.9) 
Absolute change (%) 1.1 11.9 15.3 8.6 10.1 17.0 10.1 
Relative change (%) 64.7 34.9 101.3 62.8 87.8 97.1 78.9 
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Figure 4. Reported past 30-day cannabis use from 2006 to 2016 stratified by DSM diagnosis 
 
5.3 QUESTION 2: CHARACTERISTICS ASSOCIATED WITH CANNABIS USE 
Table 12 illustrates the bivariate associations between candidate variables and past 30-
day cannabis use. A number of variables were excluded from the block modelling process as 
they were not significantly associated with past 30-day cannabis use (p<0.0001) at the bivariate 
level including: forensic assessment (reason for admission), voluntary inpatient status, social 
isolation, pain, severity of depressive symptoms, and severity of anxiety symptoms. Additional 
variables were removed if there was not at least a 5% difference in the prevalence of past 30-day 
cannabis users between any two levels of the variable. Variables excluded include: residential 
stability, lived alone, employment status, and recent psychiatric hospitalization history. 
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Table 12. Bivariate analyses of independent variables considered for the logistic regression 
model describing demographic and clinical characteristics associated with past 30-day 
cannabis use 
VARIABLE x2 p-value 
BLOCK 1 
Non-male 3297.9 <0.0001 
Age 19825.1   <0.0001 
Marital status 8000.5  <0.0001 
Education level 1041.8  <0.0001 
Indigenous origin 989.3  <0.0001 
Residential stability 35.7 <0.0001 
Lived alone 55.6  <0.0001 
Employment status 158.8  <0.0001 
Risk of unemployment/disrupted education 2653.8  <0.0001 
BLOCK 2  
Past year substance use 17241.1  <0.0001 
Past 30-day substance use 15971.1  <0.0001 
Problematic alcohol use 5119.2 <0.0001 
Smoking 14497.7 <0.0001 
Misuse of medications 1020.7  <0.0001 
BLOCK 3 
Mental 
health 
diagnosis 
Neurocognitive disorders 2815.1  <0.0001 
Substance-related and addictive disorders 14798.0 <0.0001 
Schizophrenia and other psychotic disorders 67.3 <0.0001 
Mood disorders 369.9 <0.0001 
Anxiety disorders 104.5  <0.0001 
Personality disorders  245.6  <0.0001 
Other disorders 36.4 <0.0001 
Reason for 
admission 
Threat to self 253.3 <0.0001 
Threat to others 126.3  <0.0001 
Inability to care 586.6  <0.0001 
Problem with addiction 15533.2 <0.0001 
Specific psychiatric symptoms 33.1 <0.0001 
Involvement criminal justice system 124.3  <0.0001 
Other 82.1 <0.0001 
Forensic assessment 9.5  0.0021 
Inpatient 
status at 
admission 
Application for psychiatric assessment 719.1 <0.0001 
Voluntary 8.8  0.0029 
Informal 166.5  <0.0001 
Involuntary 16.1  <0.0001 
Forensic 119.5  <0.0001 
LOS 1598.9  <0.0001 
BLOCK 4  
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Safety Harm to 
others 
History of violence 2134.2  <0.0001 
Aggressive Behaviour Scale 
(<2) 
87.4 <0.0001 
Self-harm 15.5 <0.0001 
BLOCK 5 
Social life Social 
relationships 
Social isolation 8.8 0.0031 
Dysfunction 1025.5  <0.0001 
Interpersonal conflict 556.6  <0.0001 
Traumatic life events 616.3  <0.0001 
Criminal activity 3304.5  <0.0001 
BLOCK 6 
Financial hardship 586.6 <0.0001 
Autonomy Medication adherence history 2725.0 <0.0001 
Number of psychiatric hospitalizations in prior 
2 years 
42.6 <0.0001 
Number of psychiatric hospitalizations in 
lifetime 
311.5 <0.0001 
BLOCK 7 
Health 
Promotion 
Sleep disturbance 36.6  <0.0001 
Pain 5.1  0.0771 
BLOCK 8 
Symptom 
Severity 
Positive Symptom Scale 147.8  <0.0001 
Social Withdrawal Scale 521.3  <0.0001 
Cognitive Performance Scale 1328.3 <0.0001 
Depressive Severity Index 1.0 0.3090 
Mania Scale 1784.9 <0.0001 
CAGE 15533.2 <0.0001 
Anxiety Scale 0.02  0.8812 
 
Each block was modelled separately. Within each block, several variables became 
insignificant including employment status, involvement with criminal justice system, other 
reason for admission, forensic inpatient status, aggression, and social isolation. Each 
insignificant variable was removed from the associated block, and the model was rerun. All 
blocks composed of the remaining variables were combined together one by one. Insignificant 
variables were again removed after each block was combined, and the model was rerun. 
Variables that became insignificant included: inability to care for oneself, admission due to threat 
to oneself, admission due to threat to others, harm to self, anxiety disorders, personality 
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disorders, other disorders, dysfunctional social relationships, interpersonal conflict, history of 
criminal activity, risk of unemployment or disrupted education, sleep disturbances, pain, and 
additional lifetime substance use (not including cannabis). A final model was generated with the 
remaining variables (C-statistic=0.868, Table 13).  
5.3.1 Block 1 
After controlling for other variables, sex, age, marital status, education level, and 
Indigenous origin all remained significantly associated with past 30-day cannabis use. After 
controlling for other variables, those who were married or had a partner/significant other were 
approximately 16% less likely to report being a past 30-day cannabis user relative to those who 
were never married (95% CI: 0.80-0.88). However, no significant difference was found between 
those who were widowed/separated/divorced, relative to those who were never married. 
Additionally, there was no significant difference in the odds of being a cannabis user for those 
who had less than a high school education relative to those with a high school education. 
However, those with more than a high school education were 12% less likely to be a past 30-day 
cannabis user relative to those with a high school education (95% CI: 0.85-0.91).  Finally, 
individuals who identified as being of Indigenous origin had 1.3 times greater odds of being a 
past 30-day cannabis user relative to those who did not identify as being of Indigenous origin 
(95% CI: 1.25-1.45). There was no significant difference in cannabis use status for those who 
were residentially stable versus those who were not, for those who lived alone versus those who 
did not, and those who were employed versus unemployed. There was also no significant 
difference in the odds of past 30-day cannabis use between those at risk of unemployment or of 
experiencing disrupted education. There were differences in the odds of cannabis use by year. 
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Starting in 2012, year was significantly associated with being a past 30-day cannabis user with 
the odds of past 30-day cannabis use increasing between 2012 and 2016. 
5.3.2 Block 2  
Past 30-day cannabis use was significantly associated with recent use of additional 
substances, indicators of problematic alcohol use, and being a current smoker. Those who 
reported recent use of additional substances were approximately 2.3 times more likely to report 
past 30-day cannabis use relative to those who did not report past 30-day substance use (95% CI: 
2.20-2.39). However, those who reported a lifetime use of additional substances were not more 
likely to be past 30-day cannabis users. Problematic alcohol users were 23% more likely to 
report past 30-day cannabis use (95% CI: 1.18-1.28) relative to those without problematic use. 
Finally, inpatients that reported being a smoker were 2.6 times more likely to be past 30-day 
cannabis users relative to non-smokers (95% CI: 2.54-2.72).  
5.3.3 Block 3 
After controlling for other variables, past 30-day cannabis was found to be significantly 
associated with a primary, secondary, or tertiary diagnosis of neurocognitive disorders, substance 
use disorders, schizophrenia, and mood disorders. Those with neurocognitive disorders were less 
likely to have past 30-day cannabis use (OR 0.67, 95% CI: 0.58-0.78) than those without. Those 
with mood disorders were more likely to report past 30-day cannabis use relative to those 
without (OR 1.34, 95% CI: 1.29-1.39). Past 30-day cannabis use was also significantly 
associated with LOS of the index admission; the odds of reported past 30-day cannabis use 
decreased as LOS increased. Those with the shortest LOS (3 to 14 days) were most likely to be 
past 30-day cannabis users. Individuals with a LOS from 15 to 30 days were 13% less likely to 
be past 30-day cannabis users relative to those who had a LOS 3 to 14 days (95% CI: 0.84-0.90). 
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Individuals with a LOS from 31 to 60 days were 30% (95% CI: 0.66-0.73), 61 to 90 days were 
37% (95% CI: 0.57-0.70), and those with a LOS greater than 90 days were 59% less likely (95% 
CI: 0.36-0.46) to be a past 30-day cannabis user relative to those had an index LOS 3 to 14 days. 
5.3.4 Block 4 and 5 
Past 30-day cannabis was associated with having a history of violence and experiencing 
traumatic life events. Those who had a history of violence were more likely to be past 30-day 
cannabis users (OR 1.14, 95% CI: 1.10-1.19), as were those who experienced past (OR 1.20, 
95% CI: 1.14-1.27) or current traumatic events (OR 1.18, 95% CI: 1.12-1.24). 
5.3.5 Block 6 
After controlling for other variables, experiences of financial hardship, medication 
adherence, and lifetime psychiatric hospitalization history were significantly associated with past 
30-day cannabis use. Past 30-day cannabis users were approximately 20% more likely to report 
financial hardship, which includes having a history of major loss of income or experiencing 
serious economic hardship due to poverty (95% CI: 1.16-1.24). Additionally, past 30-day 
cannabis was positively associated with medication adherence levels; decreasing medication 
adherence was associated with greater odds of being a past 30-day cannabis user relative to those 
who were always adherent to prescribed medication. Those who had no prescribed medication 
had 34% greater odds (95% CI: 1.27-1.40) of being a past 30-day cannabis user relative to those 
who had medication and were always adherent. Finally, those with greater lifetime hospital 
admissions were less likely to be recent users of cannabis. Those with 1 to 3 hospitalizations 
were 11% less likely to be past 30-day cannabis users (relative to those with no history) (95% 
CI: 0.86-0.92), and individuals with 4 to 5 hospitalizations and 6 or more hospitalizations were 
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both 21% less likely to be past 30-day cannabis users (95% CI: 0.74-0.85, 0.73-0.85, 
respectively).  
5.3.6 Block 8 
Past 30-day cannabis use remained significantly associated with several measures of 
symptoms severity after controlling for other variables. Those with more severe positive 
symptoms were 23% more likely to be past 30-day cannabis users relative to those with a score 
of 0 to 2 on the Positive Symptom Scale (95% CI: 1.18-1.28). Greater levels of social withdrawal 
were associated with reduced odds of being a cannabis user. There was no significant difference 
in the odds of being a past 30-day cannabis user for those with the least severe withdrawal 
symptoms relative to those with no symptoms (OR 0.94, 95% CI: 0.90-0.98). Those with 
moderate severity of withdrawal symptoms were 13% less likely to be past 30-day cannabis 
users (95% CI: 0.84-0.91), and those with the most severe symptoms were 17% less likely to be 
past 30-day cannabis users relative to those with no symptoms (95% CI: 0.78-0.88). Individuals 
with lower cognitive performance were less likely to be past 30-day cannabis users relative to 
those with no cognitive performance decline (OR 0.77, 95% CI: 0.71-0.83). Increasing severity 
of mania symptoms was associated with greater odds of being a past 30-day cannabis user. Those 
with the most severe mania symptoms were two times more likely to report past 30-day cannabis 
use relative to those with no mania symptoms (OR 2.0, 95% CI: 1.89-2.12). Finally, those with 
indicators of addiction (as measured by the CAGE scale), had approximately 1.2 times greater 
odds of being a past 30-day cannabis user relative to those who did not have indicators of 
addiction (95% CI: 1.14-1.24).  
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5.3.7 Interaction terms 
After controlling for other variables, significant interactions were found between sex and 
having a diagnosis of schizophrenia or other psychotic disorders, as well as, between age and 
substance-related and addictive disorders. Males with schizophrenia or other psychotic disorders 
had greater rates of cannabis use than males without this diagnosis. However, non-males with 
schizophrenia or other psychotic disorders had lower rates of cannabis use than those without 
this diagnosis (Table 14). Among males with schizophrenia and other psychotic disorders, 27.4% 
reported past 30-day cannabis use relative to 10% of non-males with this diagnosis. 
Comparatively, 23.1% of males without schizophrenia or other psychotic disorders reported past 
30-day cannabis use, relative to 14.1% of non-males without this diagnosis (Figure 5). Past 30-
day cannabis use was found to be significantly greater for individuals with a substance use 
disorder for all age categories except those 65 and older; 76.5% of those less than 18, 67.9% of 
18-24 year olds, 49.3% of 25 to 34 year olds, 33.6% of 35 to 44 year old, 23.4% of 45 to 54 year 
olds, 12.9% of those 55 to 64, and 3.8% of those 65 and older with a substance use and addictive 
disorder reported past 30-day cannabis use. These figures compare to 25.6%, 29.4%, 19.6%, 
11.2%, 8.1%, 3.9%, and 0.5% of individuals without a substance use disorder diagnosis (by age 
category) (Table 15, Figure 6).  
Table 13. Demographic and clinical characteristics included in the final predictive logistic 
regression model for individuals most likely to be past 30-day cannabis users 
VARIABLE LEVEL ODDS 
RATIO 
95% CONFIDENCE 
INTERVAL  
P-
VALUE 
Year 
(ref=2006) 
2007 1.05 0.98 1.12 0.1888 
2008 1.09 1.02 1.17 0.0099 
2009 1.01 0.94 1.09 0.7669 
2010 1.01 0.94 1.09 0.7420 
2011 1.14 1.06 1.23 0.0006 
2012 1.15 1.07 1.24 0.0002 
2013 1.27 1.18 1.37 <0.0001 
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2014 1.38 1.28 1.48 <0.0001 
2015 1.43 1.33 1.54 <0.0001 
2016 1.67 1.55 1.80 <0.0001 
BLOCK 1 
Non-male  
 
See Interaction Terms 
Age 
(ref=18-24) 
<18 
25-34 
35-44 
45-54 
55-64 
65+ 
Marital 
(ref=never 
married) 
Married/Partner/ 
Significant other 
0.84 0.80 0.88 <0.0001 
Widowed/Separated/ 
Divorced 
0.97 0.92 1.02 0.1866 
Education 
(ref=high 
school) 
< High school 1.05 1.01 1.10 0.0152 
> High school 0.88 0.85 0.91 <0.0001 
Indigenous origin 1.34 1.25 1.45 <0.0001 
BLOCK 2 
Past 30-day substance use 2.29 2.20 2.39 <0.0001 
Problematic alcohol use 1.23 1.18 1.28 <0.0001 
Smoking 2.63 2.54 2.72 <0.0001 
BLOCK 3 
Mental 
health 
diagnosis 
Neurocognitive disorders 0.67 0.58 0.78 <0.0001 
Substance-related and 
addictive disorders 
 
See Interaction Terms 
Schizophrenia and other 
psychotic disorders 
Mood disorders 1.34 1.29 1.39 <0.0001 
Reason for 
Admission 
Problem with addiction 2.01 1.93 2.09 <0.0001 
Psychiatric symptoms 1.12 1.08 1.16 <0.0001 
Inpatient 
status at 
admission 
Application for psychiatric 
assessment 
1.33 1.27 1.39 <0.0001 
Involuntary 1.22 1.16 1.30 <0.0001 
LOS 
(ref=3-14) 
15-30 days 0.87 0.84 0.90 <0.0001 
31-60 days 0.70 0.66 0.73 <0.0001 
61-90 days 0.63 0.57 0.70 <0.0001 
>90 days 0.41 0.36 0.46 <0.0001 
BLOCK 4 
History of violence 1.14 1.10 1.19 <0.0001 
BLOCK 5 
Traumatic 
life events 
Past traumatic event 1.20 1.14 1.27 <0.0001 
Current abuse 1.18 1.12 1.24 <0.0001 
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(ref=no 
history) 
BLOCK 6 
Financial hardship 1.20 1.16 1.24 <0.0001 
Medication 
adherence  
(ref=always 
adherent) 
Adherent >80% of time 1.05 1.01 1.10 0.0255 
Adherent <80% of time 1.21 1.16 1.27 <0.0001 
No medication 1.34 1.27 1.40 <0.0001 
Unknown 1.13 1.07 1.19 <0.0001 
Number of 
psychiatric 
hospitalizatio
ns in lifetime 
(ref=0) 
1-3 admissions 0.89 0.86 0.92 <0.0001 
4-5 admissions 0.79 0.74 0.85 <0.0001 
6+ admissions 0.79 0.73 0.85 <0.0001 
BLOCK 8 
Positive Symptom Scale 1.23 1.18 1.28 <0.0001 
Social 
Withdrawal 
Scale  
(ref=none) 
1,2 0.94 0.90 0.98 0.0032 
3,4,5 0.87 0.84 0.91 <0.0001 
6: More severe withdrawal 0.83 0.78 0.88 <0.0001 
Cognitive Performance Scale 0.77 0.71 0.83 <0.0001 
Mania Scale 
(ref=none) 
1 1.25 1.20 1.30 <0.0001 
2 1.56 1.50 1.63 <0.0001 
3: Most severe symptoms 2.00 1.89 2.12 <0.0001 
CAGE 1.19 1.14 1.24 <0.0001 
INTERACTION TERMS 
Interaction term Maximum 
Likelihood 
Estimate 
(β) 
Standard 
Error 
Chi-
Square 
p-value 
Schizophrenia and other psychotic 
disorders*Sex 
-0.30 0.04 61.04 <0.0001 
Substance-
related and 
addictive 
disorders*Age 
<18 0.65 0.11 35.04 <0.0001 
25-34 -0.39 0.05 74.65 <0.0001 
35-44 -0.39 0.05 65.68 <0.0001 
45-54 -0.46 0.05 85.50 <0.0001 
55-64 -0.38 0.07 29.53 <0.0001 
65+ 0.26 0.16 2.71 0.0997 
C-statistic 0.868 
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Table 14. Proportion of sample reporting past 30-day cannabis use by sex and DSM 
diagnosis of schizophrenia or other psychotic disorders 
 SEX 
DIAGNOSIS MALE 
N (%) 
NON-MALE 
N (%) 
Schizophrenia or other 
psychotic disorder 
6869 (27.4) 1762 (10.0) 
No schizophrenia or other 
psychotic disorder 
13047 (23.1) 8652 (14.1) 
 
 
 
 
Figure 5. Proportion of sample reporting past 30-day cannabis use by sex and a 
schizophrenia or other psychotic disorder diagnosis 
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Table 15. Proportion of sample reporting past 30-day cannabis use by age and DSM 
diagnosis of a substance use disorder 
 AGE 
DIAGNOSIS <18 
N (%) 
18-24  
N (%) 
25-34  
N (%) 
35-44  
N (%) 
45-54  
N (%) 
55-64   
N (%) 
65+ 
N (%) 
Substance 
use disorder 
579 
(76.5) 
5382 
(67.9) 
4787 
(49.3) 
3199 
(33.6) 
2226 
(23.4) 
591 
(12.9) 
76  
(3.8) 
No substance 
use disorder 
690 
(25.6) 
4738 
(29.4) 
3376 
(19.6) 
2139 
(11.2) 
1808 
(8.1) 
629 
(3.9) 
110  
(0.5) 
 
 
 
 
Figure 6. Proportion of sample reporting past 30-day cannabis use by age and a substance 
use diagnosis 
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5.4 QUESTION 3: 30-DAY READMISSIONS BY CANNABIS USE STATUS 
At the bivariate level, past 30-day cannabis was significantly associated with 30-day 
readmissions (p<0.0001) (Table 16). Therefore, it was important to determine whether past 30-
day cannabis use remained significantly associated with readmissions after controlling for other 
variables. The bivariate analyses to determine which variables to include in the block modelling 
process are outlined below in Table 16. 
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Table 16. Bivariate analysis for 30-day readmissions by cannabis use status 
 ALL INPTIENTS PAST 30-DAY 
CANNABIS USE 
NO PAST 30-DAY 
CANNABIS USE 
VARIABLE x2 p-value x2 p-value x2 p-value 
BLOCK 1 
Non-male 0.03 0.8676 1.0 0.3191 3.1 0.0773 
Age 660.7 <0.0001 92.4 <0.0001 493.4 <0.0001 
Marital status 335.2 <0.0001 75.4 <0.0001 213.6 <0.0001 
Residential stability 4.0 0.0449 3.7 0.0551 1.2 0.2759 
Lived alone 7.0 0.0083 1.2 0.2809 6.8 0.0089 
Employment status 67.8 <0.0001 50.3 <0.0001 33.7 <0.0001 
Risk of unemployment/disrupted education 0.3 0.5615 16.8 <0.0001 3.4 0.0661 
BLOCK 2 
Past year substance use 1.1 0.2996 5.3 0.0213 0.4 0.5416 
Past 30-day substance use 0.2 0.6937 4.4 0.0356 1.9 0.1643 
Past 30-day cannabis use  79.0 <0.0001 Not Applicable 
Problematic alcohol use 0.1 0.7639 4.4 0.0354 0.003 0.9535 
Smoking 67.0 <0.0001 1.9 0.1694 52.8 <0.0001 
Misuse of medications 19.6 <0.0001 0.7 0.4052 15.0 0.0001 
BLOCK 3 
Mental health 
diagnosis 
Neurocognitive disorders 200.8 <0.0001 0.7 0.3953 178.8 <0.0001 
Substance-related and addictive 
disorders 
47.2 <0.0001 39.6 <0.0001 60.9 <0.0001 
Schizophrenia and other psychotic 
disorders 
117.9 <0.0001 80.5 <0.0001 53.0 <0.0001 
Mood disorders 56.3 <0.0001 0.1 0.7176 77.6 <0.0001 
Anxiety disorders 6.8 0.0090 24.5 <0.0001 0.05 0.8294 
Personality disorders 86.9 <0.0001 10.3 0.0013 72.5 <0.0001 
Other disorders 3.0 0.0838 5.1 0.0235 0.4 0.5229 
Inpatient status 
at admission 
Voluntary 273.4 <0.0001 144.7 <0.0001 151.2 <0.0001 
Involuntary 10.5 0.0012 23.4 <0.0001 0.9 0.3444 
LOS 455.7 <0.0001 100.6 <0.0001 331.6 <0.0001 
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Contact with community mental health (past year) 19.5 <0.0001 0.9 0.6369 32.3 <0.0001 
BLOCK 4 
Safety Harm to 
others 
History of violence 3.8 0.0512 4.9 0.0276 0.09 0.7612 
Aggressive 
Behaviour Scale 
(<2) 
167.8 <0.0001 175.0 <0.0001 50.9 <0.0001 
Self-harm 86.7 <0.0001 2.6 0.1056 91.8 <0.0001 
BLOCK 5 
Social life Social 
relationships 
Social isolation 22.9 <0.0001 4.9 0.0262 17.3 <0.0001 
Dysfunction 0.5 0.4785 2.9 0.0908 0.5 0.4601 
Interpersonal conflict 0.0005 0.9814 0.002 0.9606 0.3 0.5554 
Traumatic life events 24.5 <0.0001 8.2 0.0166 16.3 0.0003 
Criminal activity 57.2 <0.0001 15.6 <0.0001 24.9 <0.0001 
No support system for discharge 37.8 <0.0001 22.7 <0.0001 20.4 <0.0001 
BLOCK 6 
Autonomy Medication management 0.5 0.4641 47.6 <0.0001 1.9 0.1628 
Medication adherence history 164.0 <0.0001 59.3 <0.0001 100.2 <0.0001 
Number of psychiatric 
hospitalizations in prior 2 years 
332.0 <0.0001 63.4 <0.0001 273.1 <0.0001 
Number of psychiatric 
hospitalizations in lifetime 
318.2 <0.0001 49.1 <0.0001 287.0 <0.0001 
BLOCK 7 
Health 
promotion 
Sleep disturbance 8.6 0.0034 1.4 0.2442 6.4 0.0111 
Pain 14.5 0.0007 15.2 0.0005 6.1 0.0471 
BLOCK 8 
Symptom 
severity 
Positive Symptom Scale 293.7 <0.0001 226.8 <0.0001 121.0 <0.0001 
Social Withdrawal Scale 34.5 <0.0001 2.1 0.5497 54.4 <0.0001 
Cognitive Performance Scale 17.4 <0.0001 27.2 <0.0001 29.3 <0.0001 
Depressive Severity Index 15.4 <0.0001 0.002 0.9693 20.2 <0.0001 
Mania Scale 414.2 <0.0001 193.2 <0.0001 205.0 <0.0001 
CAGE 107.1 <0.0001 76.0 <0.0001 90.5 <0.0001 
Anxiety Scale 63.4 <0.0001 7.8 0.0051 56.6 <0.0001 
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Table 17. Readmission rates among inpatients by cannabis use status and demographic and clinical variables 
 
VARIABLE 
 
LEVEL 
READMISSIONS 
ALL 
INPATIENTS 
N (%) 
PAST 30-DAY 
CANNABIS 
USE 
N (%) 
NO PAST 30-
DAY 
CANNABIS 
USE 
N (%) 
BLOCK 1 
Sex Male 5509 (6.9) 1604 (8.2) 3905 (6.5) 
Non-male 5336 (6.9) 807 (7.9) 4529 (6.8) 
Age 
 
<18 287 (8.4) 107 (8.6) 180 (8.3) 
18-24 2303 (9.8) 972 (9.8) 1331 (9.7) 
25-34 2121 (8.0) 670 (8.4) 1451 (7.9) 
35-44 1974 (7.0) 353 (6.7) 1621 (7.1) 
45-54 1921 (6.2) 232 (5.8) 1689 (6.2) 
55-64 1191 (5.9) 66 (5.5) 1125 (5.9) 
65+ 1048 (4.4) 11 (6.1) 1037 (4.4) 
Marital status Never married 6022 (8.2) 1868 (9.0) 4154 (7.9) 
Married/Partner/Significant other 2921 (5.8) 291 (5.5) 2630 (5.8) 
Widowed/Separated/Divorced 1902 (5.9)  252 (6.9) 1650 (5.7) 
Residential stability Temporary residence 2795 (7.1) 674 (8.6) 2121 (6.8) 
Non-temporary residence 8050 (6.9) 1737 (7.9) 6313 (6.6) 
Lived alone Lived alone 3238 (7.2) 671 (8.4) 2567 (6.9) 
Did not live alone 7607 (6.8) 1740 (8.0) 5867 (6.5) 
Employment Employed 2571 (6.1) 569 (6.4) 2002 (6.0) 
Not employed 8274 (7.2) 1842 (8.8) 6432 (6.9) 
Risk of unemployment/ disrupted 
education 
At risk 2781 (7.0) 799 (7.3) 1982 (6.9) 
Not at risk 8064 (6.9) 1612 (8.6) 6453 (6.6) 
BLOCK 2 
Past year substance use Yes 1877 (7.1) 966 (7.7) 911 (6.5) 
No 8968 (6.9) 1445 (8.4) 7523 (6.7) 
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Past 30-day substance use  Yes 1275 (7.0) 736 (7.6) 539 (6.3) 
No 9570 (6.9) 1675 (8.3) 7895 (6.7) 
Past 30-day cannabis use Yes 2411 (8.1) Not Applicable 
No        8434 (6.6) 
Problematic alcohol use Yes 1729 (7.0) 659 (7.6) 1070 (6.6) 
No 9116 (6.9) 1752 (8.3) 7364 (6.7) 
Smoking Yes 4604 (7.6) 1633 (8.0) 2971 (7.4) 
No 6241 (6.5) 778 (8.4) 5463 (6.3) 
Misuse of medication Yes 1594 (7.6) 470 (8.4) 1124 (7.4) 
No 9251 (6.8) 1941 (8.0) 7310 (6.5) 
BLOCK 3 
Mental health diagnosis Neurocognitive disorders 503 (3.9) 16 (6.6) 487 (3.8) 
Substance-related and addictive 
disorders  
2694 (6.2) 1195 (7.2) 1499 (5.6) 
Schizophrenia and other psychotic 
disorders 
3345 (8.1) 870 (10.4) 2475 (7.5) 
Mood disorders 6116 (7.4) 1163 (8.2) 4953 (7.2) 
Anxiety disorders 1493 (6.5) 229 (6.1) 1264 (6.6) 
Personality disorders 1164 (8.9) 302 (9.6) 862 (8.7) 
Other disorders 1408 (6.6) 265 (7.2) 1143 (6.5) 
Inpatient status at admission Voluntary 1975 (5.1) 340 (4.7) 1635 (5.2) 
Involuntary 1293 (7.5) 354 (10.2) 939 (6.8) 
LOS 
 
3-14 days 5222 (8.1) 1334 (9.3) 3888 (7.7) 
15-30 days 3797 (7.2) 819 (8.0) 2978 (7.0) 
31-60 days 1345 (4.9) 216 (5.1) 1129 (4.8) 
61-90 days 255 (4.5) 25 (4.3) 230 (4.6) 
90+ days 226 (3.8) 17 (4.2) 209 (3.8) 
Contact with community mental health No contact 5751 (6.7) 1400 (8.2) 4351 (6.3) 
0-30 days 3524 (7.3) 648 (7.9) 2876 (7.2) 
31+ days 1570 (7.1) 363 (8.2) 1207 (6.8) 
BLOCK 4 
History of violence Yes 2283 (7.2) 770 (8.6) 1513 (6.6) 
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Harm to 
others 
No 8562 (6.9) 1641 (7.9) 6921 (6.7) 
Aggressive Behaviour 
Scale 
Score >2 2108 (8.9) 645 (12.7) 1463 (7.9) 
Score ≤2 8737 (6.6) 1766 (7.3) 6971 (6.4) 
Harm to self Yes 6485 (7.5) 1400 (8.3) 5085 (7.3) 
No 4360 (6.3) 1011 (7.8) 3349 (5.9) 
BLOCK 5 
Social 
relationships 
Social isolation Yes 1396 (7.8) 322 (9.2) 1074 (7.5) 
No 9449 (6.8) 2089 (8.0) 7360 (6.5) 
Dysfunction Yes 6348 (6.9) 1576 (7.9) 4772 (6.6) 
No 4497 (7.0) 835 (8.5) 3662 (6.7) 
Interpersonal conflict Yes 6441 (6.9) 1577 (8.1) 4864 (6.6) 
No 4404 (6.9) 834 (8.1) 3570 (6.7) 
Traumatic life events No history 9014 (6.9) 1899 (8.1) 7115 (6.6) 
Current abuse 896 (6.3) 251 (7.1) 645 (6.0) 
Past traumatic event(s) 935 (7.8) 261 (9.1) 674 (7.5) 
Criminal activity Yes 3120 (7.7) 1023 (8.9) 2097 (7.3) 
No 7725 (6.6) 1388 (7.6) 6337 (6.6) 
No support system for discharge Yes 3653 (7.5) 836 (9.2) 2817 (7.1) 
No 7194 (6.7) 1575 (7.6) 5617 (6.4) 
BLOCK 6 
Medication management Needs assistance 3705 (7.0) 710 (10.1) 2995 (6.5) 
Independent 7140 (6.9) 1701 (7.5) 5439 (6.7) 
Medication adherence Always adherent 4056 (6.1) 638 (6.8) 3418 (6.0) 
Adherent >80% of time 2220 (7.0) 428 (7.8) 1792 (6.9) 
Adherent <80% of time 2348 (8.4) 640 (10.1) 1708 (8.0) 
No medication 1098 (6.8) 437 (8.2) 661 (6.1) 
Unknown 1123 (7.6) 268 (8.5) 655 (7.3) 
Number of psychiatric hospitalizations 
in prior 2 years 
0 7775 (6.4) 1699 (7.4) 6076 (6.1) 
1-2 admissions 2400 (8.5) 588 (10.3) 1812 (8.1) 
3+ admissions 670 (11.0) 124 (11.1) 546 (11.0) 
Number of psychiatric hospitalizations 
in lifetime 
0 5251 (6.0) 1268 (7.3) 3983 (5.7) 
1-3 admissions 3717 (7.5) 830 (8.9) 2887 (7.1) 
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4-5 admissions 922 (8.9) 162 (10.2) 760 (8.7) 
6+ admissions 955 (9.8) 151 (11.0) 804 (9.6) 
BLOCK 7 
Sleep disturbance Yes 5367 (7.1) 1227 (8.3) 4140 (6.8) 
No 5478 (6.7) 1184 (7.9) 4294 (6.5) 
Pain No 9479 (7.0) 2143 (8.3) 7336 (6.7) 
Medium priority 1108 (6.3) 226 (6.7) 882 (6.3) 
High priority 258 (6.6) 42 (6.1) 216 (6.8) 
BLOCK 8 
Positive Symptoms Scale 0-2: No or mild symptoms 6483 (6.2) 1210 (6.3) 5273 (6.1) 
3+: More severe symptoms 4362 (8.5) 1201 (11.1) 3161 (7.8) 
Social Withdrawal Scale 
 
0: No withdrawal 2312 (6.3) 646 (8.2) 1666 (5.8) 
1,2 3240 (6.9) 790 (8.2) 2450 (6.5) 
3,4,5 3855 (7.2) 729 (7.8) 3115 (7.0) 
6+: More severe withdrawal 1449 (7.5) 246 (8.5) 1203 (7.3) 
Cognitive Performance Scale 0-2: No or mild impairment 9935 (7.0) 2261 (7.9) 7674 (6.8) 
 
3+: More severe impairment 910 (6.1) 150 (12.1) 760 (5.6) 
Depressive Severity Index 0-2: No or mild depression 4352 (6.6) 1018 (8.1) 3334 (6.3) 
3+: More severe depression 6493 (7.1) 1393 (8.1) 5100 (6.9) 
Mania Scale 
 
0: No mania symptoms 4386 (6.1) 694 (6.2) 3692 (6.1) 
1 2656 (6.6) 556 (7.3) 2100 (6.4) 
2 2344 (7.6) 655 (9.2) 1689 (7.1) 
3: Most severe symptoms 1459 (10.8) 506 (13.0) 953 (9.9) 
CAGE 0-1: No potential problem with 
addiction 
8988 (7.3) 
 
1608 (9.3) 7380 (6.9) 
 
2+: Potential problem with 
addiction 
1857 (5.6) 803 (6.5) 
 
1054 (5.1) 
Anxiety 0-2: No or mild anxiety 8650 (6.7) 1940 (7.9) 6710 (6.4) 
3+: More severe anxiety 2195 (8.0) 471 (9.1) 1724 (7.8) 
78 
 
5.4.1 Readmissions among all inpatients 
After controlling for other variables, the main effect for past 30-day cannabis use did not 
remain significantly associated with 30-day readmissions for all inpatients. However, past 30-
day cannabis did increase readmissions for those exhibiting positive symptoms; a significant 
interaction was found between past 30-day cannabis use and positive symptoms, suggesting that 
cannabis users exhibiting positive symptoms are at an increased risk of readmission relative to 
recent users without these symptoms or those with positive symptoms who have not had past 30-
day cannabis use. Among past 30-day cannabis users, 11.3% of those with positive symptoms 
were readmitted within 30 days of discharge relative 6.3% without positive symptoms. Among 
non-past 30-day cannabis users, 7.8% of those with positive symptoms were readmitted within 
30-days relative to 6.1% of those without positive symptoms (Figure 7). This relationship 
became more pronounced when readmissions within one year of discharge were considered 
(Figure 8). Additional variables that predicted 30-day readmissions included age, employment, 
mood disorders, personality disorders, having a voluntary inpatient status, length of stay, 
aggression, having no support system at discharge, recent and lifetime psychiatric hospitalization 
history, social withdrawal severity, mania symptom severity, and problem with addiction (Table 
18).  
Table 18. Results of the multi-variable logistic regression analysis for 30-day hospital 
readmissions among all individuals in inpatient psychiatry from 2006 to 2016 
VARIABLE LEVEL ODDS 
RATIO 
95% CONFIDENCE 
INTERVAL 
P-
VALUE 
BLOCK 1 
Age 
(ref=18-24) 
<18 0.81 0.72 0.93 0.0018 
25-34 0.84 0.88 0.89 <0.0001 
35-44 0.72 0.67 0.77 <0.0001 
45-54 0.62 0.58 0.66 <0.0001 
55-64 0.57 0.53 0.62 <0.0001 
65+ 0.45 0.42 0.49 <0.0001 
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Employment status 0.85 0.82 0.91 <0.0001 
BLOCK 3 
Mental health diagnosis Mood 
disorders 
1.24 1.18 1.29 <0.0001 
Personality 
disorders 
1.15 1.08 1.23 <0.0001 
Inpatient status at 
admission 
Voluntary 0.83 0.78 0.87 <0.0001 
LOS 
(ref=3-14 days) 
15-30 days 0.91 0.87 0.95 <0.0001 
31-60 days 0.64 0.61 0.69 <0.0001 
61-90 days 0.56 0.49 0.64 <0.0001 
90+ days 0.46 0.40 0.53 <0.0001 
BLOCK 4 
Aggressive Behaviour Scale (>2) 1.17 1.10 1.24 <0.0001 
BLOCK 5 
No support system for discharge 1.10 1.05 1.15 <0.0001 
BLOCK 6 
Number of psychiatric 
hospitalizations in prior 
2 years 
(ref=0) 
1 to 2 1.12 1.06 1.19 0.0002 
3+ 1.30 1.18 1.43 <0.0001 
Number of psychiatric 
hospitalizations in 
lifetime 
(ref=0) 
1 to 3 1.17 1.11 1.24 <0.0001 
4 to 5 1.35 1.24 1.47 <0.0001 
6+ 1.53 1.40 1.67 <0.0001 
BLOCK 8 
Social Withdrawal  
Scale 
(ref=none) 
1,2 1.06 1.0 1.12 0.0349 
3,4,5 1.12 1.06 1.18 0.0001 
6+: More 
severe 
withdrawal 
1.20 1.12 1.29 <0.0001 
Mania Scale 
(ref=none) 
1 1.01 0.96 1.06 0.7192 
2 1.07 1.01 1.13 0.0180 
3: Most severe 
symptoms 
1.35 1.25 1.45 <0.0001 
CAGE 0.83 0.78 0.87 <0.0001 
INTERACTION TERMS 
 Maximum 
Likelihood 
Estimate 
Standard 
Error 
Chi-
Square 
p-value 
Positive Symptom Severity*Past 30-day 
cannabis 
0.31 0.05 39.45 <0.0001 
C-statistic 0.631 
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Figure 7. Readmissions within 30 days of discharge by past 30-day cannabis use status and 
presence of positive symptoms6 
 
Figure 8. Readmissions within 1 year of discharge by past 30-day cannabis use status and 
presence of positive symptoms 
                                                 
6 Positive symptoms are measured with the Positive Symptom Scale. 
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5.4.2 Readmissions among past 30-day cannabis users 
As cannabis use was associated with higher rates of readmissions at the bivariate level, a 
separate model was developed to examine predictors of readmissions specifically among past 30-
day cannabis users (Table 19). For past 30-day cannabis users, age was significantly associated 
with 30-day readmissions. There was no significant difference in 30-day readmission rates for 
individuals less than 18 years old (p=0.1148), 25 to 34 years old (p=0.1481), and older than 65 
(p=0.1598) relative to those 18 to 24 years old after controlling for other factors. However, 
individuals aged 35 to 64 who reported past 30-day cannabis had lower odds of being readmitted 
within 30-days relative to cannabis users 18 to 24. Additionally, those with a voluntary inpatient 
status at admission were less likely to be readmitted within 30-days relative to those that had any 
other inpatient status (OR 0.70, 95% CI: 0.61-0.79).  For past 30-day cannabis users, length of 
stay was significantly associated with readmission rates; decreasing length of stay was associated 
with greater odds of being readmitted. However, there was no significant difference in odds of 
being readmitted for past 30-day cannabis users with a LOS 3 to 14 days relative to those with a 
LOS from 15 to 30 days (OR 0.84, 95% CI: 0.77-0.92, p=0.0003). Past 30-day cannabis users 
with a length of stay from 31 to 60 days had approximately half the odds of being readmitted 
within 30-days relative to those with a LOS from 3 to 14 days (OR 0.56, 95% CI: 0.48-0.65). 
Past 30-day cannabis users with a LOS from 61 to 90 days were 60% less likely to be readmitted 
within 30-days (OR 0.41, 95% CI: 0.27-0.62), and those with LOS 90 or more days had 
approximately 73% decreased odds (OR 0.37, 95% CI: 0.23-0.61) of being readmitted within 30-
days relative to those who had a length of stay 3 to 14 days.  Past 30-day cannabis users who 
were admitted with aggressive behaviour were 1.5 times more likely to be readmitted within 30 
days relative to those without indicators of aggression (95% CI: 1.32-1.62). Recent psychiatric 
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hospitalization history was also found to be associated with 30-day readmissions for past 30-day 
cannabis users; a greater number of hospitalizations in the past two years was associated with 
greater odds of being readmitted within 30-days. Those with 3 or more admissions in the past 
two years were approximately 50% more likely to be readmitted within 30 days relative to those 
who had no recent admissions (95% CI: 1.24-1.83). Positive symptom severity was a predictor of 
30-day readmissions for past 30-day cannabis users. Those with more severe positive symptoms 
had increased odds of being readmitted within 30 days (OR 1.49, 95% CI: 1.36-1.64). Finally, 
past 30-day cannabis users who had a potential problem with addiction were less likely to be 
readmitted within 30-days of discharge (OR 0.82, 95% CI: 0.75-0.90). 
Table 19. Results of the multi-variable logistic regression analysis for 30-day hospital 
readmissions among individuals reporting past 30-day cannabis use 
VARIABLE LEVEL ODDS 
RATIO 
95% CONFIDENCE 
INTERVAL 
P-
VALUE 
BLOCK 1 
Age 
(ref=18-24) 
<18 0.84 0.68 1.04 0.1148 
25-34 0.93 0.83 1.03 0.1481 
35-44 0.76 0.67 0.86 <0.0001 
45-54 0.66 0.57 0.77 <0.0001 
55-64 0.59 0.46 0.77 <0.0001 
65+ 0.64 0.35 1.19 0.1598 
BLOCK 3 
Inpatient status at 
admission 
Voluntary 0.70 0.61 0.79 <0.0001 
LOS 
 (ref=3-14) 
15-30 days 0.84 0.77 0.92 0.0003 
31-60 days 0.55 0.48 0.65 <0.0001 
61-90 days 0.41 0.27 0.62 <0.0001 
90+ days 0.37 0.23 0.61 <0.0001 
BLOCK 4 
Aggressive Behaviour Scale (>2) 1.46 1.32 1.62 <0.0001 
BLOCK 6 
Number of psychiatric 
hospitalizations in 
prior 2 years (ref=0) 
1 to 2 1.38 1.25 1.53 <0.0001 
3+ 1.50 1.24 1.83 <0.0001 
BLOCK 8 
Positive Symptom Scale 1.49 1.36 1.64 <0.0001 
CAGE 0.82 0.75 0.90 <0.0001 
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C-statistic 0.641 
5.4.3 Readmissions among non-past 30-day cannabis users 
Variables associated with 30-day readmissions for non-past 30-day cannabis users were 
identified (Table 20). After controlling for all other variables, age remained significantly 
associated with 30-day readmissions. Similar to past 30-day cannabis users, increasing age was 
generally associated with a reduced likelihood of being readmitted. Non-cannabis users less than 
18 years did not have significantly different readmission rates relative to 18 to 24-year olds 
(p=0.0043). However, non-cannabis users 25 and older were less likely to be readmitted relative 
to 18 to 24-year olds. The odds of being readmitted for those age 25 and older decreased for each 
older age category. Being employed was protective against readmissions for non-cannabis users 
(OR 0.86, 95% CI: 0.81-0.90). Mood disorders was the only diagnostic category significantly 
associated with readmissions for non-past 30-day cannabis users. Those diagnosed with a mood 
disorder were approximately 1.3 times more likely to be readmitted within 30 days of discharge 
relative to those without a mood disorder diagnosis (95% CI: 1.20-1.32). Inpatients with a 
voluntary inpatient status were less likely to be readmitted, similar to past 30-day cannabis users. 
However, non-recent users were only 17% less likely to be readmitted, relative to a 31% less 
likely for those who were past 30-day cannabis users. Similar to past 30-day cannabis users, 
those who did not use cannabis use in the past 30 days who had longer LOS had decreased odds 
of being readmitted within 30 days. However, this relationship only became significant for LOS 
greater than 30 days. Additionally, recent psychiatric hospitalization history was positively 
associated with 30-day readmissions. There was no significant difference in readmissions among 
those with 0 versus 1 to 2 recent lifetime admissions (p=0.0029). This relationship became 
significant when recent admissions increased to 3 or more in the last two years; those with 3 or 
more recent hospitalizations had 36% increased odds of being readmitted within 30-days relative 
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to those with no recent hospitalization history. 30-day readmissions were also significantly 
associated with lifetime psychiatric hospitalization history for non-past 30-day cannabis users; 
the odds of readmission increased as the number of lifetime hospitalizations increased. Those 
with the most lifetime admissions (6 or more) were 1.6 times more likely to be readmitted 
relative to those without any lifetime admissions (95% CI: 1.42-1.72).  Positive symptom 
severity was also a significant predictor of 30-day readmissions for non-past 30-day cannabis 
users. Those with more severe positive symptoms were 15% more likely to be readmitted within 
30-days of discharge relative to those with less severe and no positive symptoms (95% CI: 1.09-
1.21). Severity of mania symptoms and social withdrawal were also significantly associated with 
readmissions with increasing severity being more strongly associated with readmissions. Non-
cannabis users with the greatest social withdrawal were 23% more likely to be readmitted within 
30-days (95% CI: 1.13-1.33), and those with the more severe mania symptoms were 43% more 
likely to be readmitted (95% CI: 1.32-1.55). Finally, non-past 30-day cannabis users who had a 
potential problem with addiction were less likely to be readmitted within 30-days of discharge 
(OR 0.82, 95% 0.77-0.88). 
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Table 20. Results of the multi-variable logistic regression analysis for 30-day hospital 
readmissions among individuals reporting no past 30-day cannabis use 
VARIABLE LEVEL ODDS 
RATIO 
95% CONFIDENCE 
INTERVAL 
P-
VALUE 
BLOCK 1 
Age 
(ref=18-24) 
<18 0.79 0.67 0.93 0.0043 
25-34 0.81 0.75 0.87 <0.0001 
35-44 0.71 0.66 0.77 <0.0001 
45-54 0.61 0.56 0.65 <0.0001 
55-64 0.56 0.52 0.61 <0.0001 
65+ 0.44 0.41 0.48 <0.0001 
Employment status 0.86 0.81 0.90 <0.0001 
BLOCK 3 
Mental health 
diagnosis 
Mood disorder 1.26 1.20 1.32 <0.0001 
Inpatient status at 
admission 
Voluntary 0.83 0.79 0.88 <0.0001 
LOS 
(ref=3-14) 
15-30 days 0.93 0.88 0.98 0.0037 
31-60 days 0.67 0.62 0.72 <0.0001 
61-90 days 0.60 0.52 0.68 <0.0001 
90+ days 0.49 0.43 0.57 <0.0001 
BLOCK 6 
Number of 
psychiatric 
hospitalizations in 
prior 2 years (ref=0) 
1 to 2 1.11 1.04 1.18 0.0029 
3+ 1.36 1.22 1.51 <0.0001 
Number of 
psychiatric 
hospitalizations in 
lifetime (ref=0) 
1 to 3 1.18 1.12 1.26 <0.0001 
4 to 5 1.38 1.26 1.52 <0.0001 
6+ 1.57 1.42 1.72 <0.0001 
BLOCK 8 
Positive Symptom Scale 1.15 1.09 1.21 <0.0001 
Social Withdrawal 
Scale (ref=none) 
1,2 1.09 1.03 1.17 0.0067 
3,4,5 1.17 1.10 1.25 <0.0001 
6: More severe 
withdrawal 
1.23 1.13 1.33 <0.0001 
Mania Scale 
(ref=none) 
1 1.02 0.96 1.07 0.6009 
2 1.09 1.02 1.16 0.0092 
3: Most severe 
symptoms 
1.43 1.32 1.55 <0.0001 
CAGE 0.82 0.77 0.88 <0.0001 
C-statistic 0.623 
 
 
86 
 
5.4.4 Summary: Readmissions among past 30-day cannabis users versus non-users 
After controlling for other factors found to be significantly associated with readmissions, 
no significant association was found between 30-day readmissions and cannabis use status 
among all inpatients (p=0.1941). However, those exhibiting positive symptoms who used 
cannabis had increased risk of 30-day readmission. Different factors were found to be associated 
with 30-day readmissions depending on past 30-day cannabis use status (Table 21). Additionally, 
some factors were more strongly associated with readmissions for each cannabis status group. 
For both groups, it was found that those who stayed longer in hospital had lower risk of being 
readmitted within 30 days of discharge. Recent hospitalization history was a stronger predictor of 
readmissions for past 30-day cannabis users compared to non-recent users. Individuals with 1 to 
2 recent admissions who were cannabis users were 38% more likely to be readmitted (95% CI: 
1.25-1.53), relative to only a 10% increase in odds of being readmitted for non-recent users (95% 
CI: 1.04-1.18). Both groups had greater odds of being readmitted with increasing number of 
recent psychiatric hospital admissions. Finally, higher aggressive behaviour scale scores were a 
predictor of readmissions for past 30-day cannabis users but not for non-past 30-day cannabis 
users.  
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Table 21. Variables significantly associated with 30-day readmissions for all inpatients, 
past 30-day cannabis users, and non-past 30-day cannabis users 
ALL INPATIENTS 
(Model 1) 
PAST 30 DAY CANNABIS 
USE 
 (Model 2) 
NO PAST 30-DAY 
CANNABIS USE 
 (Model 3) 
Increase 
Odds 
Decrease 
Odds 
Increase 
Odds 
Decrease 
Odds 
Increase 
Odds 
Decrease 
Odds 
Younger age 
Mood disorder 
Personality 
disorder 
Shorter LOS 
More 
aggressive 
behaviour 
No support 
system for 
discharge 
> Lifetime 
admissions 
> Recent 
admissions 
More severe 
positive 
symptoms 
Higher level 
of social 
withdrawal 
More severe 
mania 
symptoms 
 
Employed 
Voluntary  
inpatient 
status 
Problem with 
addiction 
 
Younger age 
Shorter LOS 
More 
aggressive 
behaviour  
> Recent 
admissions 
More severe 
positive 
symptoms 
 
Voluntary  
inpatient 
status 
Problem with 
addiction 
Younger age 
Mood disorder 
Shorter LOS 
> Lifetime 
admissions 
> Recent 
admissions 
More severe 
positive 
symptoms 
Higher level 
of social 
withdrawal 
More severe 
mania 
symptoms 
 
Employed 
Voluntary 
inpatient 
status 
Problem with 
addiction 
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CHAPTER 6: DISCUSSION 
Due to large gaps in current cannabis literature, many of the public health impacts of non-
medical cannabis legalization remain largely unknown. This study explored the patterns of past 
30-day cannabis use among individuals in inpatient psychiatry in Ontario, Canada. The present 
study established trends in past 30-day cannabis use among those in inpatient psychiatry across a 
10-year period (2006 to 2016), identified characteristics associated with those most likely to 
report being a past 30-day cannabis user, and determined whether past 30-day cannabis use was 
associated with increased risk of 30-day readmissions. The importance and relevance of this 
study’s findings will be presented and can be used to guide future research and public health and 
education campaigns that aim to reduce the negative impacts of cannabis use in those living with 
and who are at risk of mental health conditions. 
6.1 PREVALENCE AND TRENDS IN CANNABIS USE 
To our knowledge, this was the first study to establish prevalence rates and trends in 
cannabis use for an entire inpatient psychiatric population. The findings will, therefore, be 
primarily compared to previous literature that has evaluated cannabis use in the general 
population and to subsets of other mental health populations.  
Cannabis use is commonly understood to be more prevalent among persons with mental 
health conditions than the general population. In two studies that assessed cannabis use in 
individuals with mental health conditions, 19.5% and 9.9% of participants reported cannabis use, 
relative to 10.3% and 1.3% of individuals without mental illnesses, respectively (1,2). Although 
cannabis has been commonly measured in the broader mental health population, studies 
assessing the prevalence of substance use specifically in the inpatient population are limited. A 
small-scale study evaluating cannabis use in adolescent psychiatric inpatients found 13% to 
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report lifetime cannabis use (87). In the present study, from 2006 to 2016, 18.9% of inpatients 
reported past 30-day cannabis use. This compares to studies of the general Canadian population 
that have found cannabis use to range from 12.3% for use within the past year (23) to 14% based 
on medical and non-medical use within the past three months (88). Together, these findings 
confirm that those in inpatient psychiatry use cannabis more than the general population and in 
similar amounts to other mental health populations.  A challenge to note while comparing 
prevalence estimates is the scale for reporting; the current study used past month use while 
others report prior 90 days, 12 months, and lifetime measures. Having a broader definition of 
past 30-day cannabis use may have increased the prevalence found in the current study. 
Throughout the study period, increases in reported rates of past 30-day cannabis were 
observed. In 2006, 15.4% of the inpatient population reported past 30-day cannabis use 
compared to 25.3% in 2016, attributing to a relative change of 64.3%. While the cause of this 
trend cannot be identified using the existing data, it does raise questions about the potential 
impact of changing culture, perception, legal status, and social acceptability of a cannabis on the 
availability, risk perception, and usage of cannabis. Research from the United States has found 
that cannabis use has increased, and risk perception has decreased during the time where 
significant changes in the legal environment of cannabis (both medical and non-medical) have 
occurred (89,90).  Thus, the question of whether cannabis use will increase following 
legalization arises. Increasing cannabis use among psychiatric inpatients is cause for further 
investigation, with a particular need to tease out whether the cannabis use is associated with the 
person’s need for inpatient psychiatric care or whether an increasing trend is representative of a 
changing attitude about disclosing cannabis use. If increased rates of use are seen in the general 
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population post-legalization, rates of use in the inpatient psychiatric population should be 
established and should be stratified by demographic and clinical characteristics. 
For some diagnostic groups, there were both increases in the number of individuals being 
admitted into psychiatric hospitals and in the proportion of individuals reporting cannabis over 
time (e.g., substance-related and addictive disorders, and anxiety disorders). For other diagnostic 
categories, there were decreases in admissions over time while the proportion of individuals 
reporting past 30-day cannabis use increased (e.g., schizophrenia and other psychotic disorders, 
and personality disorders). These patterns raise the question of how cannabis relates to an 
admission into inpatient psychiatry for each mental health condition. Although admissions into 
inpatient psychiatry for some diagnostic groups decreased despite cannabis use increasing, this 
may be related to the availability of community resources for certain mental health conditions. 
For instance, it may be that community resources for schizophrenia and other psychotic disorders 
have increased in the community during the time where admissions have decreased which has 
reduced the need of inpatient psychiatric care for this population. Regardless of the actual 
number of individuals being admitted into inpatient psychiatry, the proportion of cannabis users 
increased across nearly all diagnostic groups. Continual monitoring is needed to determine how 
rates of admission change for all diagnostic groups following legalization, and how this relates to 
changes in rates of cannabis use.  
Starting at the beginning of 2018, a new survey is being administered quarterly by the 
Canadian government which captures information on cannabis use (88). This survey will be an 
important tool for monitoring how prevalence and patterns of cannabis use in the general 
population compare to trends in use in the inpatient population, which has been captured on the 
RAI-MH since 2005. It is also important to monitor the characteristics of individuals in inpatient 
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psychiatry who are recent users of cannabis. This can give insight into whether certain 
populations begin to use cannabis more, whether cannabis adversely affects their mental health, 
or whether users experience improved mental health and clinical outcomes. 
6.1.1 Age 
As per the general population, younger individuals in inpatient psychiatry report greater 
cannabis use. Among most age groups, use has increased over time with a slight decrease seen in 
those less than 18.7 Higher and increasing use among younger age groups is of particular concern 
for several reasons. First, this trend indicates a possible association between increased use of 
cannabis and an increased need for mental health services among younger age groups. This is 
evidenced by the increase seen in both reported cannabis use among younger groups and among 
admission rates (Table 10, Table 28). Second, there is reason to anticipate that use within 
younger cohorts will continue to increase following legalization. This hypothesis is rooted in the 
idea that following legalization the perceived risk associated with cannabis will decrease. As the 
perceived risk of a substance decreases, use of that substance tends to increase, particularly 
among younger individuals (91). Increased rates of cannabis use among youth and adolescents 
raises concern as earlier initiation of use has been associated with long-term adverse 
psychosocial outcomes that may persist for an individual’s lifespan (26,27,30,92). This 
knowledge depicts why it is important for use among youth to be discouraged. Youth need to be 
informed on the potential harms associated with cannabis use and how to adopt safer, age-
appropriate consumption habits through public health efforts, including integration of necessary 
information into school curriculums. Particular emphasis should be placed on abstinence among 
                                                 
7 This decrease is likely a sample size issue as very few persons under 18 are admitted to adult 
beds per year. 
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youth and warning labels that describe the risk of adverse mental health outcomes (e.g., risk of 
psychosis).  The government has already alluded to measures that aim to reduce use among 
youth, such as the proposed use of plain packaging (comparable to tobacco products), use of 
warnings on packages, and careful consideration for storefront locations and legal age of 
purchase (93).  
Despite rates of use historically being higher in younger age categories, increases in 
reported cannabis use were seen in older age groups. Use among older age groups pose their own 
unique considerations. For instance, a concern for older adults in inpatient psychiatry, and 
healthcare more generally, is the problematic use of substances. Older adults have typically not 
been thoroughly assessed for their substance use behaviours (94). With easier access to cannabis 
following legalization, it is imperative that all individuals presenting to inpatient psychiatry are 
adequately screened for substance use behaviours as identifying problematic substance use 
patterns is critical from a treatment perspective. Monitoring older age groups, where cannabis 
use has historically been low, can also help to understand whether there are any unique and 
unanticipated experiences in this population. Exploring use in this population is important as 
current research on the efficacy and safety of cannabis (for both medical and non-medical 
cannabis) has failed to uniquely consider the impact of cannabis use on this population (95). 
Although increases in use among all populations may be due to increased non-medical 
use, more doctors may also be prescribing medical cannabis for the alleviation and management 
of health conditions. The current study does not differentiate between medical and non-medical 
use indicating that these figures may capture medical cannabis use. The increase seen among 
older adults, therefore, may be attributable to increases in physician prescriptions for medical 
cannabis and not non-medical use. Although cannabis may be beneficial for physical health 
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conditions, it is important to consider whether this has any negative cognitive impacts over time. 
Futuristic studies that differentiate between medical and non-medical cannabis can give insight 
into reasons for and type of use among different age cohorts, and measure whether medical 
cannabis has any adverse mental health effects.  
6.1.2 Sex 
The patterns of cannabis use by sex among the inpatient psychiatric population were 
consistent with trends in the general population, with a higher prevalence among males than non-
males. However, our findings show that there has been a greater increase in the prevalence of 
cannabis use among non-males over time. From 2006 to 2016 there was a 54.4% relative 
increase in past 30-day cannabis use among males, and an 82.5% relative increase among non-
males. Some researchers suggest that the gap between male and female users may narrow with 
legalization and as social acceptability increases. It may be that women who currently feel social 
pressure to abstain from cannabis become more accepting once the legal status of the drug 
changes (96), or that females may be more willing to openly discuss their cannabis use 
behaviours. 
To date, little research has focused on sex-specific effects of cannabis with animal studies 
primarily using males, and studies failing to conduct sex-stratified analyses (97). Sex-stratified 
analyses may reveal how the brain is affected by cannabis and the different motivations behind 
cannabis use (98). For instance, some researchers propose that women are more likely to use 
cannabis for suppression of anxiety than men (29), and that cannabis may actually be able to 
decrease anxiety levels for females but not for males (99). Variations in effects may be due, in 
part, to differences in muscle mass and fatty tissue distribution in males and females (98). With 
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increased use among females, it is important to monitor and evaluate sex-specific differences of 
cannabis use on mental health disorders for those in inpatient psychiatry.  
6.1.3 Mental Health Diagnosis 
The prevalence of cannabis use was highly variable between diagnostic groups. However, 
rates of use increased for all diagnostic group over time. Among those with schizophrenia and 
other psychotic disorders, 23% reported past 30-day cannabis use. Within this population, the 
percentage of individuals reporting past 30-day cannabis nearly doubled, despite the absolute 
number of persons in this diagnostic group decreasing over time (see Appendix C). Rates of use 
in this population were consistent with prior literature that has established a strong relationship 
between cannabis use and psychosis. Green, Young, and Kavanagh (100) found that, of 14 
studies that looked at current cannabis use (n=1695), 23% of individuals with psychosis and 
those exhibiting positive symptoms reported current cannabis use. The current study confirms 
this high rate of use on a more acute level and with a larger study population. Another study by 
Myles, Myles and Large (101) found higher rates of cannabis use among individuals 
experiencing first episode psychosis than rates found in this study. Thus, it may be important to 
consider whether individuals being admitted for their first time have higher rates of use than 
individuals with a known history of psychosis. Higher rates of use may be expected among 
individuals with first-episode psychosis as cannabis has been associated with the onset of 
psychotic symptoms in those with a genetic predisposition (34). Research suggests that after an 
initial diagnosis, the odds of being a continued cannabis user decrease by half (101). The 
inclusion of individuals with first-episode psychosis and those with a prior known history of 
psychosis may account for lower prevalence observed in this general diagnostic category 
compared to first episode samples. This particular diagnostic group is important to monitor over 
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time to determine whether increased use of cannabis in the general population (a possible 
outcome of cannabis legalization), is accompanied by a change in the prevalence and incidence 
of hospitalizations for first-episode schizophrenia and other psychotic disorders, and/or for those 
presenting with psychotic symptoms.  
The prevalence of past 30-day cannabis use may be anticipated to increase in certain 
diagnostic groups following legalization. For instance, use among those with mood and anxiety 
disorders may increase as there is a common notion that cannabis can help with anxiety and 
depressive symptoms. However, it is important to assess whether those who turn to cannabis 
actually receive symptom relief. Research that evaluates the effects of cannabis on anxiety and 
depression has been bidirectional and suggests that the effects of cannabis are dependent on 
several factors such as the dose (102), strain (48), and specific diagnosis (47,48). If the general 
public is not informed about these differences and this complex relationship, individuals may not 
receive the intended effects. Increased admissions for anxiety and depressive disorders, and 
increased rates of use within these diagnostic categories could suggest that an increasing number 
of people are turning to cannabis with the aim to reduce their depressive or anxiety symptoms. 
Analysis is needed to determine whether people are receiving the intended benefits from 
cannabis or whether they experience adverse events following cannabis initiation.  
 Among individuals with a primary, secondary, or tertiary diagnosis of a substance-related 
and addictive disorder, 38% reported cannabis use. Thus, cannabis is not the problematic 
substance for over two thirds of individuals with a SUD diagnosis. Although cannabis may not 
be driving a SUD diagnosis for the majority of individuals in inpatient psychiatry, it may serve 
as the primary substance driving this diagnosis for certain subgroups. For instance, youth tend to 
be primarily cannabis users and thus, a substance-related diagnosis among this cohort may be an 
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indication that cannabis is the problematic substance (see Section 6.2). This suggests that 
although addressing and discouraging use may not improve treatment outcomes and mental 
health status for all persons, it may improve treatment outcomes for certain subgroups (e.g., 
youth). 
Summary 
If an increase in cannabis use is seen following legalization, is important to consider the 
demographic characteristics that describe these individuals. For instance, if a greater number of 
younger individuals begin to use cannabis, longitudinal changes in the prevalence of particular 
diagnoses should be assessed. This is important as cannabis use in youth has been associated 
with long-term mental health outcomes, including the development of psychotic disorders for 
those with a genetic predisposition (34). Overall, the characteristics describing cannabis users in 
inpatient psychiatry should be monitored, and long-term impacts should be explored. 
6.2 CHARACTERISTICS ASSOCIATED WITH CANNABIS USE 
Demographic characteristics of cannabis users in inpatient psychiatry generally align with 
those of the general population. As per the general population, sex was found to be significantly 
associated with being a cannabis user with males being greater users than non-males. 
Additionally, higher rates of use were found among younger individuals, those who were never 
married (relative to those who were married or who had a partner/significant other), individuals 
identifying as being of Indigenous origin, and those with a high school or lower level of 
education (relative to those with higher than a high school education). Living alone, living in a 
temporary residence, or being at risk of unemployment/experiencing disrupted education were 
not significantly associated with past 30-day cannabis use. 
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The strength of the relationship between both sex and age and cannabis use interacted 
with the presence of specific mental health diagnoses. Having a primary, secondary, or tertiary 
diagnosis of schizophrenia or another psychotic disorder increased the odds of being a past 30-
day cannabis user for males. However, there was no difference in the prevalence of past 30-day 
cannabis use for females based on this diagnosis. This finding may be related to the idea that 
males in general are more likely to report cannabis use than non-males. However, it may also 
relate to the idea that males and females have been suggested to metabolize and experience 
cannabis differently (98). Although this is among the first studies to report a differential pattern 
of cannabis use among those with psychosis by sex, the impact of cannabis has been noted to 
differ by sex for other diagnosis groups (e.g., anxiety) (99). This warrants further investigation to 
better understand why males with schizophrenia or another psychotic disorder are more likely to 
be past 30-day cannabis users than non-males. Age was also significantly associated with past 
30-day cannabis use, with the strength of the relationship being dependent on the presence of a 
SUD. Not surprisingly, among all age groups, cannabis use was higher in those with SUDs than 
in those without. However, considerably higher rates of cannabis use were found in younger 
cohorts with a SUD relative to older cohorts. As cannabis is the most commonly used substance 
among younger cohorts, the question arises of whether cannabis is the problematic substance for 
younger age groups, with others driving this diagnosis for older individuals with SUDs. Future 
studies should evaluate whether younger cohorts with SUDs also report the use of additional 
substances, or whether cannabis is the primary problematic substance being used that is leading 
to this diagnosis. In summary, there is a need to further evaluate to what extent cannabis is the 
problematic substance, particularly for younger age categories.  
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High rates of polysubstance use were found among those reporting past 30-day cannabis 
use. Nearly half of individuals with either a lifetime or recent history of other substance use 
(including inhalants, hallucinogens, cocaine and crack, stimulants and opiates) also reported use 
of cannabis. After controlling for other variables, recent, but not lifetime, use of other substances 
increased the odds of being a past 30-day cannabis user. Problematic alcohol use was also 
associated with past 30-day cannabis use. The distinction between someone who is an exclusive 
cannabis user versus someone who problematically uses other substance is essential as 
polysubstance use has been understood to differentially affect a person’s mental health compared 
to cannabis use alone. Research indicates that cannabis alone may not influence more adverse 
mental health states and more complex symptomology, but that cannabis use in addition to other 
substances may (103). Thus, polysubstance use should be uniquely considered and evaluated 
when trying to understand mental health states and to improve clinical outcomes. All research 
that aims to identify the public health implications of cannabis use needs to consider 
polysubstance use specifically to evaluate whether cannabis itself is problematic to mental health 
states, or whether other substances may be the source of the problem. 
Prevalence of past 30-day cannabis was variable among mental health diagnoses, with 
some groups having higher odds of reporting recent use where others had decreased odds. 
Individuals with neurocognitive disorders were less likely to be past 30-day cannabis users, a 
finding not surprising considering that this group is largely made up of older persons, persons 
with lower levels of cognitive performance and greater levels of dependence. Persons with other 
diagnoses had increased odds of being a past 30-day cannabis user including those with 
substance-related and addictive disorders, schizophrenia and other psychotic disorders, and mood 
disorders. Concerns arise as cannabis use has been identified as problematic for some diagnostic 
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categories by contributing to more adverse social and clinical outcomes (see Section 2.4 and 
2.5). Use among certain diagnostic groups may also contribute to an index admission by 
inducing undesirable psychiatric symptoms, such as acute cannabis-induced psychosis, that may 
subside after use is ceased (104), and that may not have occurred had cannabis not been used. 
Differentiating between cannabis-induced mental health states and those with a biological source 
is important from a treatment perspective, as one may be treated with abstinence of cannabis use, 
while the one may require additional medication and treatment. The strength of these 
relationships should be monitored to determine whether the odds of being a past 30-day cannabis 
user increase for some diagnostic groups following legalization. 
Cannabis has been understood to be widely used among persons with PTSD with 
symptom management being a commonly cited reason for use (105-108). In the inpatient 
population, individuals with both a past history and those experiencing current trauma had 
increased odds of being a past 30-day cannabis user. There is an extensive body of literature that 
has identified a strong relationship between experiences of trauma and cannabis use. In a study 
that evaluated the relationship between cannabis use and having PTSD, cannabis use remained 
significantly associated with this diagnosis after controlling for sociodemographic factors and a 
co-diagnosis of an anxiety or mood disorders (109). Although the present study has not explicitly 
studied those with PTSD, the relationship between trauma and cannabis use has been confirmed 
on a large scale, and in a representative sample including those in inpatient psychiatry (109). 
Once cannabis is legalized, some individuals may seek to self-medicate their PTSD symptoms 
rather than consult a physician. It is imperative that the public is adequately informed about risks 
associated with self-medication, including the importance of strain differentiation (110).  
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Additional characteristics were found to be differentially associated with cannabis use 
status. Higher rates of cannabis use were found in those with shorter lengths of stay; the odds of 
being a past 30-day cannabis user decreased as LOS increased. This finding is consistent with 
other literature that has found cannabis users to have shorter lengths of stay in inpatient 
psychiatry (62,63). The shorter lengths of stay seen among cannabis users raise an important 
question of whether cannabis use contributed to the admission into inpatient psychiatry; it may 
be that once an individual is admitted and stops using cannabis, their symptoms subside leading 
to a quick discharge. This notion is consistent with other researchers’ proposition that that a 
shorter length of stay commonly seen in cannabis users may be due to substance-induced 
cognitive distortion and symptom exacerbation, rather than there being an underlying etiological 
worsening or relapse of a mental illness (62,63). Findings from this study also found that those 
with a shorter length of stay had increased risk of readmission. Together, these findings point to 
the importance of substance use behaviours being adequately assessed and addressed among all 
individuals so that positive clinical outcomes can be supported. Failure to address substance use 
behaviours during an admission may lead to individuals re-using once they are discharged which 
may then contribute to an increased risk of readmission if their substance use contributed for the 
need for an admission in the first place. Overall, differentiating between cannabis-induced 
psychosis versus mental health conditions with an etiological basis is relevant from a treatment 
perspective as one may be treatable with cannabis abstinence, while the other may require more 
complex care. 
Lifetime hospitalization history, but not recent hospitalization history, was significantly 
associated with past 30-day cannabis use. Those with a greater number of lifetime psychiatric 
hospitalizations had reduced odds of being a current cannabis user. It may be that these 
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individuals have abstained from cannabis as they have previously found cannabis to worsen their 
clinical symptoms and to contribute to their need to be admitted. This finding may also be related 
to greater use being present among those with no previous hospitalizations; individuals 
experiencing a first episode may have higher rates of cannabis use. Those with reduced levels of 
medication adherence were also found to have greater odds of being a past 30-day cannabis use. 
These findings raise the question of whether individuals not adherent to their medication are 
substituting prescriptions with cannabis, and whether those with no medication are receiving 
cognitive benefits (including symptom management) from cannabis. Motivators for use among 
those who are not adherent to their medications and among those with no psychotropic 
medication should be evaluated to determine whether they are aiming to control their psychiatric 
symptoms with cannabis, rather than with prescribed medications. Additionally, those with no 
medication had increased rates of cannabis use. Having no current medications may signify a 
first admission to a mental health hospital. The degree to which cannabis may have contributed 
to this first admission must be considered. 
Overall, individuals with more complex and severe clinical symptoms had increased odds 
of reporting past 30-day cannabis use. For instance, those exhibiting positive symptoms had 
significantly increased odds of reporting past 30-day cannabis use relative to those who did not 
trigger this scale. Additionally, those presenting with the most severe mania symptoms were two 
times more likely to be a past 30-day cannabis user relative to those with no mania symptoms. 
As symptoms severity has been linked to more costly care (111,112), it is important for futuristic 
studies to determine if, or to what extent, cannabis is contributing to adverse clinical symptoms. 
Understanding the impact of cannabis use on clinical symptoms can help to determine whether 
interventions that aim to reduce cannabis use is a means to improve clinical outcomes and 
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decrease healthcare expenditures. It may also be of interest to track symptom severity for 
cannabis users following legalization. CBD has been proposed to aid in symptom management 
for some conditions (48). More research is being produced to further explore this relationship. 
Thus, being able to choose a cannabis strain in legal storefronts that has reduced THC 
concentration and elevated CBD levels, including pure concentrated CBD, may help to reduce 
the severity of undesirable symptoms lead to benefits to, rather than worsening of, mental health 
symptoms (20,21). Thus, if cannabis users are informed about different cannabis components 
and choose strains with higher CBD levels, there may be suppression, rather than exacerbation, 
of psychiatric symptoms.  
Summary 
Identifying factors associated with cannabis use can be used to understand a myriad of 
challenges and/or vulnerabilities that a person may face. Although this study cannot determine 
the degree to which cannabis use itself is a primary reason for a person’s mental health 
condition, understanding these factors may guide future research in teasing out problematic 
cannabis use from non-problematic use. It may be important to target interventions towards 
subpopulations that are most likely to be past 30-day cannabis users only if cannabis is seen to 
contribute to adverse mental health outcomes and higher healthcare costs. For instance, among 
persons experiencing a first psychotic episode and reporting cannabis users, interventions should 
include education or counselling to prevent further cannabis use. The current study has identified 
characteristics of those most likely to be a past 30-day cannabis user among those in inpatient 
psychiatry. This information can be used to follow individuals longitudinally to explore mental 
health and clinical outcomes.  
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Identifying the current characteristics associated with people who report using past 30-
day cannabis can also be used to monitor whether these identifiers change over time. As 
discussed, with impending legislation more people may be inclined to try or use cannabis when it 
becomes legalized. Results from the first quarter National Cannabis Survey suggest that there 
may be an increase in the number of people using cannabis following legalization; 6% of 
respondents who did not use cannabis in the past three months indicated that they would try 
cannabis or increase their consumption levels once non-medical cannabis is legalized (88). A 
change in the demographic and clinical characteristics of users can help to depict whether 
cannabis may be problematic for new users. Following individuals with characteristics outlined 
in Table 13 through time, can be used to determine whether those most likely to past 30-day 
cannabis users have more adverse clinical outcomes or need costlier mental health care.  
6.3 QUESTION 3: 30-DAY READMISSIONS BY CANNABIS USE STATUS 
The risk of being readmitted within 30-days of discharge for individuals in inpatient 
psychiatry reporting past 30-day cannabis use was evaluated. After controlling for other factors 
known to increase the risk of readmission within the psychiatric population, past 30-day cannabis 
users presenting with positive symptoms had increased rates of readmission relative to cannabis 
users without these symptoms. As those exhibiting positive symptoms were also found to have 
increased rates of cannabis use, it is imperative that rates of use within this population are 
reduced so that risk of readmission can be also lessened, and positive clinical outcomes can be 
supported. Literature suggests that cannabis use may be related directly to the readmission as 
those experiencing psychotic symptoms who use cannabis at baseline but who stop using after an 
admission have shown to have improved patient outcomes (113).  
104 
 
The relationship between psychosis and readmissions has been well documented (66,67). 
To our knowledge, this is the first study to link past 30-day cannabis use among those with 
positive symptoms specifically to increased risk of readmission in such a large representative 
sample. Previous studies have typically been conducted in small samples and have been 
criticized for failing to adjust for confounders (e.g., other substance use) (55). In this study’s 
population, 11.3% of those presenting with positive symptoms who used cannabis were 
readmitted within 30-days of discharge relative to 7.8% of those with no positive symptoms. 
Among those with no positive symptoms, nearly equal rates of readmission were found in both 
the cannabis and non-cannabis use groups (Figure 7). This finding suggests that the risk of 
readmission among cannabis users is dependent on the presence of positive symptoms. This 
relationship became even more pronounced when readmissions within one year of discharge 
were considered (Figure 8). This finding points to the importance of education and intervention 
programs that aim to reduce cannabis use among those with positive symptoms as continued 
cannabis use may contribute to exacerbation of positive symptoms thus increasing the need for 
psychiatric intervention.  
Regardless of cannabis use status, similar demographic and clinical factors were found to 
be associated with readmissions. However, there were fewer predictors of readmissions for past 
30-day cannabis users. Some of the key factors associated with readmissions will be discussed to 
understand how cannabis use may relate to readmissions among the inpatient population. 
Overall, the factors associated with readmissions for this population were highly associated with 
psychosis and indicate mental health conditions that are more difficult to effectively treat. The 
inability for patients to receive the care that they need due to more complex clinical profiles may 
be a reason for readmission, rather than cannabis itself influencing the readmission. 
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The literature generally suggests that younger individuals have increased odds of being 
readmitted (66). However, among past 30-day cannabis users, those 65 years and older did not 
have significantly different rates of readmission than those 18 to 24 (p=0.1598). For non-
cannabis users, the risk of readmission significantly decreased with increasing age. This indicates 
that cannabis may negatively affect cognitive states and treatment progression for older 
individuals. It is important to monitor patient outcomes for this population, as they may begin to 
use more once access to cannabis is made easier and social acceptability increases. It is important 
to assess readmission rates among older populations if they begin to use cannabis more following 
legalization.   
Aggressive behaviour was identified as a risk factor for 30-day readmissions for past 30-
day cannabis users only. However, aggressive behaviour was not associated with cannabis use 
status indicating that past 30-day cannabis users are not more likely to be aggressive than non-
cannabis users. This indicates that there is something about aggression that increases the risk of 
readmissions for past 30-day cannabis users. It may be that those scoring high on the ABS are 
more difficult to treat due to the refusal of treatment. Thus, these individuals may not be 
receiving the amount of care that they need before being discharged. If substance use behaviours 
are not discussed and managed during their stay, they may return to substance use following 
discharge leading to an earlier readmission. Focusing treatment efforts on reducing aggressive 
behaviour (for instance, by providing anger management strategies) and substance use 
behaviours may help to reduce readmission rates among past 30-day cannabis users specifically. 
This relationship may also be related to the idea that there tends to be two distinct populations of 
aggressive individuals in inpatient psychiatry; those with dementia and other neurocognitive 
disorders, and those with psychosis or other conditions. Older individuals are less likely to be 
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past 30-day cannabis users and are also less likely to be readmitted into inpatient psychiatry as 
those who need continuing care may be admitted to other facilities (e.g., nursing and long-term 
care homes). Thus, age as well as diagnosis may be confounding this relationship. This 
population should be studied longitudinally to determine whether cannabis may be a source of 
agitation, and if ceasing use helps to decrease aggression levels, and thus readmission risk. 
Surprisingly, scoring higher on the CAGE scale, which measures problem with addiction, 
was protective against a 30-day readmission for both past 30-day cannabis users and non-recent 
users. Both subgroups had 18% reduced odds of being readmitted within 30-days relative to 
those who did not score high on this measure. As they both are at equal risk of being readmitted, 
it may be that cannabis does not differentially affect the risk of readmission for those with 
problematic substance use. There may be other substances more highly related to a readmission. 
Problem with addiction not being associated with readmissions may be explained by the idea that 
those being admitted with SUDs only, with no other secondary or tertiary diagnosis, tend to be 
higher functioning and thus are less likely to be readmitted (64). Those with concurrent mental 
health and SUDs, rather than a mental health or SUD alone, however, are at increased risk for 
future readmissions (64). Despite individuals typically spending a shorter time in hospital, those 
with concurrent disorders usually have higher health care use due to more frequent readmissions 
(64). This information suggests that in order to limit the risk of readmission it is imperative that 
both the mental health and SUD be considered in care planning. Another important consideration 
is that SUDs did not significantly predict readmissions for either past 30-day cannabis users or 
non-users. However, this may be explained by the idea that SUDs are often underdiagnosed in 
the inpatient setting (64). The CAGE scale embedded into the RAI-MH may be a useful tool that 
captures substance use issues that may not have been diagnosed as an actual mental health 
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disorder. Individuals who trigger the CAGE scale should be further screened for SUDs and 
aspects of care planning should consider addressing substance use issues in order to decrease an 
individual’s readmission risk.  
Summary  
Cannabis use was found to be related to 30-day readmissions for those exhibiting positive 
symptoms. Reducing cannabis use in this population is crucial to improve patient outcomes and 
decrease health care costs. Factors associated with increased risk for readmissions in each 
subgroup can also be used to identify individuals who may be at increased risk of readmissions 
and can be used to inform care planning so that risk of readmission can be reduced. 
6.4 POLICY IMPLICATIONS AND PRACTICE 
This research points to the importance of ongoing monitoring and evaluation of cannabis 
use in the inpatient setting following legalization of non-medical cannabis. Baseline trends and 
relationships of cannabis use in the inpatient psychiatric population have been identified and 
need to be continually evaluated to determine whether changes in the legal status of the drug 
affects those living with and who are at risk of mental health conditions. Following this 
population longitudinally will help to evaluate whether they have been adequately protected and 
can be used to identify gaps in policy that need to be addressed.  It is important to evaluate 
whether changes in the patterns and prevalence of cannabis use in the entire Canadian population 
has any implications for inpatient psychiatry. 
Some policy recommendations can be made from this work to date. As previously 
discussed, cannabis use at younger ages has been associated with adverse psychosocial 
outcomes. However, as evidenced by high rates of use among youth in this population, youth 
continue to be significant users of cannabis. This indicates that this population is either not aware 
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of the risk of cannabis use, or that they do not see these risks as a concern. It is crucial for 
warning labels that inform about the adverse mental health and social outcomes for youth are 
included on all cannabis products. Additionally, school curriculums need to reflect changes in 
the legal status and accessibility of cannabis so that if youth do choose to use, they are informed 
on cannabis constituents (including the differentiation between THC and CBD), the 
physiological effects of cannabis, and the known risks of use. This can help to ensure that they 
adopt safer consumptions habits and can identify adverse physical and psychological reactions 
that would indicate that use should be ceased.  
Literature is beginning to emerge on potential drug interactions between cannabis and 
prescription medications (17,114). If individuals have the perception that cannabis helps with 
mental health conditions, and they begin to use cannabis while on other medications, there is 
need to clarify whether cannabis has either an additive or diminishing effect on the prescribed 
medications. In order to ensure that individuals are adequately protected and do not experience 
adverse effects, an open dialogue between patients and physicians must be encouraged. Those 
taking medications to aid in symptom management, for instance, should be informed about 
potential interactions and should be encouraged to report adverse effects to their physicians. A 
central reporting system that tracks these interactions can help clinicians stay informed so that 
they can warn their patients of safe consumptions patterns, and about whether specific strains 
have contributed to adverse experiences.  
Following legalization, problematic substance use behaviours must be screened for in all 
populations, not just populations that have been historically known to be greater users of 
cannabis. For instance, although older populations have tended to have lower rates of cannabis 
use, they may be inclined to use following legalization. SUDs are commonly underdiagnosed in 
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older populations (94) which is problematic from a treatment perspective. Substance use 
behaviours need to be evaluated in all populations and should be integrated into care planning to 
maximize positive clinical outcomes.  
Finally, cannabis use was found to be associated with increased risk of readmission for 
those with positive symptoms. Labels on cannabis products should include information on the 
risk of psychosis and should encourage abstinence for those with a known history/heightened 
risk of psychosis. It is important that those with psychotic disorders and those expressing 
positive symptoms are informed about the increased risk for adverse psychological experiences 
so that they use can be ceased and undesirable symptoms can be avoided.  
6.5 FUTURE RESEARCH 
A number of future areas for research were mentioned throughout the discussion. In 
general, this study opens the conversation about cannabis use in inpatient psychiatry and has 
identified avenues where follow-up studies are needed. As this study broadly describes the 
relationship between cannabis use and mental health outcomes, further analysis should be 
considered to determine whether mental health outcomes vary by patterns of cannabis use and 
not just cannabis use in the general sense. For instance, additional consumption behaviours such 
as the dose of cannabis used, the typical route of administration, the frequency of use, and strain 
of use are important as the effects of cannabis have been noted to vary by these factors (12). 
Thus, it may be useful to conduct qualitative research to obtain more information about 
individual patterns of cannabis use. 
A key change from the DSM-IV to DSM-V definition of mental health disorder 
diagnoses was the separation of bipolar and depressive disorders. Prior to the DSM-V, bipolar 
and depressive disorders were both captured under the umbrella diagnostic category of mood 
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disorders. Once more data is collected with this diagnostic distinction, the analyses can be 
separated to determine whether readmissions are different for bipolar and depressive disorders. 
Given the findings related to mania symptoms in this study, it may be that cannabis use is more 
common among individuals with bipolar disorder. There is a need to determine whether such use 
is detrimental to ongoing recovery.  
6.6 LIMITATIONS  
Some limitations arise due to the retrospective design of the study and the data collection 
methods. One key limitation is that information obtained from inpatients on their cannabis use 
history can sometimes be primarily collected using self-report, although other information 
sources can be used. As cannabis is currently an illicit substance, individuals may be 
apprehensive to accurately report on cannabis use (115). This may lead to underreporting of use 
among individuals in inpatient psychiatry. However, for many patients, data is also collected 
from the other key informants including family, first responders, and other clinical staff who may 
be more willing to accurately state the individual’s cannabis use status. Use of multiple key 
informants can help to mitigate the potential of obtaining inaccurate information from patients 
themselves. Additionally, underreporting suggests that our results will be modest in nature and 
thus some relationships may not be as strong as they actually are, and other relationships may 
appear to be non-significant when there is a true relationship.  
There are also several limitations that exist due to the retrospective nature of the study. 
As follow-up questions cannot be asked and the RAI-MH is a pre-constructed assessment tool, 
we are unable to decipher whether reported cannabis is being used for medical or non-medical 
purposes. Although this can provide grounds for a future study, individuals using medically 
prescribed cannabis may not be receiving the intended benefits if it has not been helpful in 
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disease and symptom management. Another potential limitation is that findings can only be 
generalized as far as the inpatient psychiatric population and cannot be assumed to reflect the 
general mental health population. Those with mental health disorders capture a larger population 
than that of the specific inpatient population. Had information on community mental health 
clients been available, for instance, the prevalence of past 30-day cannabis use may be expected 
to increase. With the increasing use of compatible assessment tools, such as the interRAI 
Community Mental Health, more information about the patterns of cannabis use in the 
community can be ascertained in future studies. 
Finally, a key gap in the literature is understanding the temporal relationship between 
cannabis use and mental health. Although we were able to establish relationships between 
cannabis use and aspects of mental health, this study did not allow us to establish a temporal 
relationship. As data use is collected retrospectively, we are limited in being able to understand 
whether cannabis use or mental illness came first. 
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APPENDIX 
APPENDIX A: OPERATIONALIZATION OF VARIABLES 
Table 22. Operationalization of dependent variables for logistic regression models 
VARIABLE OPERATIONALIZATION 
Past 30-day 
cannabis use 
Binary: 
• Past 30-day cannabis use 
• No past 30-day cannabis use 
Readmissions Binary:  
• 30-day readmission 
• No 30-day readmission 
 
Table 23. Operationalization of independent variables used in logistic regression models 
VARIABLE OPERATIONALIZATION 
Year Ordinal: 
• 2006 (ref) 
• 2007 
• 2008 
• 2009 
• 2010 
• 2011 
• 2012 
• 2013 
• 2014 
• 2015 
• 2016 
BLOCK 1: DEMOGRAPHIC FACTORS 
Sex Nominal: 
• Male (ref) 
• Non-male  
Age Ordinal: 
• <18 
• 18-24 (ref) 
• 25-34 
• 35-44 
• 45-54 
• 55-64 
• 65+ 
Marital status Nominal: 
• Never Married (ref) 
• Married/Partner/Significant Other  
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• Widowed/Separated/Divorced 
Education level Ordinal: 
• Less than high school 
• High school (ref) 
• Greater than high school 
Indigenous 
origin 
Nominal: 
Yes/no answered to, “Person’s origin is Inuit, Métis or First Nations” 
• Not Inuit, Métis, or First Nations (ref) 
• Inuit, Métis, or First Nations 
Residential 
stability 
Nominal: 
Yes/no answered to, “Prior to admission, most recent residence was 
temporary” 
• No temporary residence (ref) 
• Temporary residence 
Lived alone Nominal: 
• Did not live alone (ref) 
• Lived alone 
Employment 
status 
Nominal: 
• Employed 
• Unemployed (ref) 
Risk of 
unemployment/ 
disrupted 
education 
Yes/no answered to any of the following items:  
 
Increase in lateness or absenteeism over the last 6 months 
Poor productivity or disruptiveness at work/school 
Expresses intent to quit work/school 
Persistent unemployment or fluctuating work history over the last 2 years 
 
Nominal: 
• Answered yes to at least one of the above 
• Did not answer yes to any of the above (ref) 
BLOCK 2: SUBSTANCE USE 
Past year 
substance use 
Answered yes to past year use of any of the following substances: 
 
Inhalants 
Hallucinogens 
Cocaine and Crack 
Stimulants 
Opiates 
 
Nominal: 
• Use of any of the above in the past year 
• No use of any of the above in the past year (ref) 
Past 30-day 
substance use 
Answered yes to past 30-day use of any of the following substances: 
 
Inhalants 
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Hallucinogens 
Cocaine and Crack 
Stimulants 
Opiates 
 
Nominal: 
• Use of any of the above in the past 30-days 
• No use of any of the above in the past 30-days (ref) 
Problematic 
alcohol use 
Nominal: 
• Consumed 5+ drinks in a single sitting in the past two weeks 
• Consumed <5 drinks in a single sitting in the past two weeks (ref) 
Smoking Nominal: 
• Daily smoker or usually a daily smoker of cigarettes or chewing tobacco 
• Not a daily smoker or user of chewing tobacco (ref) 
Misuse of 
medications 
Nominal: 
Answered yes/no to “Use of medication for a purpose other than intended 
in the past 3 months” 
• Did not use medication for purpose other than intended (ref) 
• Used medication for purpose other than intended  
BLOCK 3: CLINICAL VARIABLES 
Mental health 
diagnosis8 
Nominal: 
 
• Neurocognitive disorders 
• Substance-related and addictive disorders 
• Schizophrenia and other psychotic disorders 
• Mood disorders (including depression) 
• Anxiety disorders 
• Personality disorders  
• Other9 
Reason for 
admission 
Nominal: 
  
Answered yes/no to the following items (each item assessed separately and 
multiple can be selected): 
 
• Threat or danger to self 
• Threat or danger to others 
                                                 
8 Considered primary, secondary, and tertiary diagnosis 
9Includes: neurodevelopmental disorders; mental disorders due to general medical conditions; 
somatoform disorders; factitious disorders; dissociative disorders; sexual and gender identity 
disorders; eating disorders; sleep-wake disorders; disruptive, impulse-control and conduct 
disorders; adjustment disorders; obsessive-compulsive and related disorders; trauma- and 
stressor-related disorders; elimination disorders; sexual dysfunction; paraphilic disorders; other 
mental disorders; and medication-induced movement disorders and other adverse effects of 
medication 
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• Inability to care for self due to mental illness 
• Problem with addiction/dependency 
• Specific psychiatric symptoms 
• Involvement with criminal justice system 
• Other 
• Forensic assessment 
Inpatient status 
at admission 
Nominal: 
• Application for psychiatric assessment 
• Voluntary 
• Informal 
• Involuntary 
• Forensic 
Past year 
contact with 
community 
mental health 
Ordinal: 
• No contact in the last year (ref) 
• 31 days or more 
• 30 days or less 
LOS Ordinal: 
• 3 to 14 days (ref) 
• 15 to 30 days 
• 31 to 60 days 
• 61 to 90 days 
• > 90 days 
CLINICAL INDICATORS 
BLOCK 4: SAFETY 
Variable Measures Operationalization 
Harm to others History of 
violence 
 
• Violence towards others 
• Intimidation of others or 
threatened violence 
• Violent ideation 
• History of sexual violence or 
assault as perpetrator  
Answered yes to any 
of the measures 
 
Binary: 
• No history of 
violence (ref) 
• History of violence  
Aggressive 
Behaviour 
Scale 
 
 
• Verbal abuse 
• Physical abuse 
• Socially inappropriate/disruptive 
• Resists care 
 
Scores range from 0 to 12 
 
Higher scores related to greater 
frequency and diversity of 
aggressive behaviour.  
Binary: 
• Score ≤2 (ref) 
• Score >2  
Self-harm  History of 
suicide attempt 
Categorical: 
• No suicide attempt history (ref) 
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• History of hurting oneself but not with intent to kill self 
• Intent of self-injury was to kill oneself 
 History of self-
injury/behavio
ur 
 
Binary: 
• No suicide attempt or self-injury history (ref) 
• Some history  
BLOCK 5: SOCIAL LIFE  
Social 
relationships 
Social 
isolation 
• Reports of having no confidant 
• Participation in social activities 
of long-standing interest 
• Withdrawal from activities of 
interest or long-standing 
relations 
• Reduced social interaction 
• Presence/absence of telephone 
or email contact with long-
standing social relation/family 
member 
Binary: 
• Having a confidant 
(ref) 
• Having no confidant 
and any of the above 
 
 
Relationship 
dysfunction 
• Belief that relationship(s) with 
immediate family members is 
disturbed or dysfunctional 
• Family/close friends report 
feeling overwhelmed by 
person’s illness 
• Conflict-laden or severed 
relationship, including divorce 
Binary: 
• Did not answer yes 
to any of the 
measures (ref) 
• Answered yes to any 
of the measures  
Support person for discharge • Presence of support person post-
discharge 
• Homeless status 
• Presence of individual who feels 
positive about discharge 
Binary: 
• Has support system 
for discharge (ref) 
• The individual does 
not have someone to 
provide support  
Interpersonal conflict • Belief that relationship(s) with 
immediate family members is 
disturbed or dysfunctional 
• Reports having no confidant 
• Family/close friends report 
feeling overwhelmed by 
person’s illness 
• Is persistently hostile towards or 
critical of family/friends 
• Is persistently hostile of others 
or staff 
Binary: 
• Did not answer yes 
to any of the 8 items 
(ref) 
• Answered yes to at 
least one of the 8 
measures  
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• Family/friends are persistently 
hostile towards or critical of 
person 
• Staff reports persistent 
frustration in dealing with 
person 
• Family/friends require unusual 
amounts of facility staff time 
Traumatic life events Assesses immediate safety 
concerns: 
• Experience traumatic event in 
the past 7 days including sexual 
abuse, physical abuse, emotional 
abuse, criminal victimization; 
OR 
• Are fearful of others or currently 
have concerns for personal 
safety 
 
Reduce the impact of prior 
traumatic events: 
• Have experienced: serious 
accident or physical impairment, 
death of a close family member 
or friend, lived in a war zone or 
area of violent conflict, witness 
severe accident/disaster/act of 
terrorism or violence/abuse, 
victim of crime, victim of sexual 
assault or abuse, victim of 
physical assault or abuse, victim 
of emotional assault or abuse; 
AND 
• Describe the event(s) as having 
evoked an intense sense of 
horror or fear 
Nominal: 
• No traumatic life 
events (ref) 
• Facing immediate 
safety concerns (i.e., 
any type of abuse or 
fear for personal 
safety) 
• History of traumatic 
life events 
Criminal activity • Past year police intervention 
• Admission from correctional 
facility 
Binary: 
• No criminal history 
(ref)  
• Past year history of 
violent or nonviolent 
criminal behaviour 
in which there was 
police intervention  
BLOCK 6: FINANCIAL HARDSHIP AND AUTONOMY 
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Financial hardship Major loss of income or serious 
economic hardship due to poverty 
Binary: 
• Never (ref) 
• Lifetime history  
Medication management  
 
Measure of IADLs 
 
Assesses ability to manage 
medication (e.g. remembering to 
take medications, open bottles, 
take correct drug dosages, give 
injections, apply ointments) 
Binary: 
• Manage medication 
independently (ref) 
• Some degree of 
assistance 
(Supervision, limited 
assistance, extensive 
assistance, maximal 
assistance, total 
dependence)  
Medication adherence Adherence to prescribed 
medications 1 month prior to 
admission 
Ordinal: 
• Always adherent 
(ref) 
• Adherent 80% or 
more of time 
• Adherent less than 
80% of time, 
including failure to 
purchase prescribed 
medication 
• No medication 
prescribed 
• Unknown 
Recent psychiatric admissions Number of recent (last 2 years) 
psychiatric admissions 
Ordinal: 
• None (ref) 
• 1 to 2 
• 3 or more 
Lifetime psychiatric admissions Number of lifetime psychiatric 
admissions 
Ordinal: 
• None (ref) 
• 1 to 3 
• 4 to 5 
• 6+ 
Independence (IADL) • Meal preparation 
• Ordinary housework 
• Managing finances 
• Managing medications 
• Phone use 
• Shopping 
• Transportation 
 
Scores range from 0 to 
42 
 
Higher scores indicate 
lower capacity 
 
Ordinal: 
• 0 to 2 (ref) 
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 • 3 to5 
• 6+ 
BLOCK 7: HEALTH PROMOTION  
Sleep disturbance Sleep problems present in the past 
3 days including: difficulty falling 
asleep, restless or non-restful 
sleep, interrupted sleep (including 
awakening earlier than desired), 
or too much sleep 
Dichotomized: 
• No sleep 
disturbances (ref) 
• Sleep disturbance  
Pain Frequency and intensity of pain Ordinal: 
• No pain or less than 
daily mild to 
moderate pain (ref) 
• Daily mild to 
moderate pain 
• Severe, horrible or 
excruciating pain 
(regardless of 
frequency) 
BLOCK 9: SYMPTOM SEVERITY**  
Cognitive Performance Scale • Daily decision making 
• Short-term memory 
• Expression (i.e., making self 
understood) 
• Self-performance in eating 
Scores summed and 
range from 0 to 6 with 
higher scores 
indicating greater 
impairment 
 
Ordinal: 
• Score 0 to 2 (ref) 
• Score 3+ 
 
Depression Severity Index (DSI) • Sad, pained facial expression 
• Negative statements 
• Self-deprecation 
• Guilt/shame 
• Hopelessness 
 
Scores range from 0 to 
15 
 
Higher scores indicate 
more depressive 
symptoms 
 
Ordinal:  
• Score of 0 to 2 (ref) 
• Score 3+  
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Positive Symptom Scale PSS Short: 
• Hallucinations 
• Command hallucinations 
• Delusions 
• Abnormal thought process 
 
PSS short scores range 
from 0 to 12 
 
Higher scores indicate 
higher levels of 
positive symptoms 
 
Ordinal:  
• Score of 0 to 2 (ref) 
• Score 3+  
Social Withdrawal Scale • Decreased energy 
• Flat or blunted affect 
• Anhedonia 
• Loss of interest 
• Lack of motivation 
• Reduced social interaction 
Scores range from 0 to 
6 
 
Higher scores indicate 
greater social 
withdrawal 
 
Ordinal: 
• No social 
withdrawal (ref) 
• Scores of 1 or 2  
• Scores of 3 to 5 
• Score of 6 
 
Mania Scale • Inflated self-worth 
• Hyperarousal 
• Irritability 
• Increased 
sociability/hypersexuality 
• Pressured speech 
• Labile affects 
• Sleep problems due to 
hypomania 
Scores range from 0 to 
20 
 
Higher scores indicate 
more mania symptoms  
 
Ordinal: 
• No symptoms of 
mania (ref) 
• Scores of 1 to 3 
• Scores of 4 to 8 
• Score of 9+ 
 
Problem with addiction 
(CAGE)  
• Need to cut down on substance 
use 
• Angered by criticisms from 
others 
• Guilt about substance use 
• Drinking/using substances in the 
morning 
Scores range from 0 to 
4 
 
Scores of 2+ indicates 
that there may be a 
potential problem with 
substance addiction 
 
Ordinal: 
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• Scores <2 (ref) 
• Scores 2+  
Anxiety Scale • Anxious complaints 
• Fears/phobias 
• Obsessive thoughts 
• Compulsive behaviours 
• Intrusive thoughts/flashbacks 
• Episodes of panic 
Scores range from 0 to 
6 
 
Higher scores indicate 
greater levels of 
anxiety 
 
Ordinal: 
• Scores ≤2 (ref) 
• Score >2  
** Adapted from (116) 
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APPENDIX B: CROSSWALKED DSM-IV AND DSM-V CODES 
 
Table 24. Breakdown of DSM diagnoses from 2014 RAI-MH assessment with DSM-IV 
codes and 2016 RAI-MH assessment with DSM-V codes 
OLD RAI-MH ASSESSMENT NEW RAI-MH ASSESSMENT 
Disorders of childhood/adolescence  Neurodevelopmental disorders 
Delirium, dementia and amnestic and other 
cognitive disorders 
Neurocognitive disorders 
Mental disorders due to general medical 
conditions 
Not Applicable 
Substance-related disorders Substance-related and addictive disorders 
Schizophrenia and other psychotic disorders Schizophrenia and spectrum and other 
psychotic disorders 
Mood disorders Bipolar and related disorders 
Depressive disorders 
Anxiety disorders Anxiety disorders 
Somatoform disorders Somatic symptoms and related disorders 
Factitious disorders Not Applicable 
Dissociative disorders Dissociative disorders 
Sexual and gender identity disorders Gender dysphoria  
Eating disorders Feeding and eating disorders 
Sleep disorders Sleep-wake disorders 
Impulse-control disorders not classified 
elsewhere 
Disruptive, impulse-control and conduct 
disorders 
Adjustment disorders Not Applicable 
Personality disorders Personality disorders 
 
 
New Categories 
Obsessive-compulsive and related disorders 
Trauma- and stressor-related disorders 
Sexual dysfunctions 
Paraphilic disorders 
Medication-induced movement disorders 
and other adverse effects of medication 
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APPENDIX C: FREQUENCY TABLES FOR POPULATION SAMPLES 
Table 25. Number and percentage of inpatients by year 
YEAR FREQUENCY 
N (%) 
2006 20827 (13.0) 
2007 16911 (10.6) 
2008 15303 (9.5) 
2009 14666 (9.2) 
2010 13915 (8.7) 
2011 13588 (8.5) 
2012 13387 (8.4) 
2013 13266 (8.3) 
2014 13204 (8.2) 
2015 12580 (7.9) 
2016 12685 (7.9) 
TOTAL 160322 (100.0) 
 
Table 26. Number and percentage of inpatient in each sex category by year 
 
 
 
 
 
 SEX 
YEAR Male 
N (%) 
Non-male 
N (%) 
2006 10579 (50.8) 10248 (49.2) 
2007 8471 (50.1) 8440 (49.9) 
2008 7583 (49.6) 7720 (50.5) 
2009 7441 (50.7) 7225 (49.3) 
2010 7165 (51.5) 6750 (48.5) 
2011 7006 (51.6) 6582 (48.4) 
2012 6763 (50.5) 6624 (49.5) 
2013 6632 (50.0) 6634 (50.0) 
2014 6781 (51.4) 6423 (48.6) 
2015 6517 (51.8) 6063 (48.2) 
2016 6543  (51.6) 6142 (48.4) 
TOTAL 81481 (50.8) 76651 (49.2) 
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Table 27. Number and percentage of inpatients in each diagnostic category by year 
 
 
 
 
 
 
 
 
 
 
 
 
 
 DIAGNOSTIC GROUP 
YEAR Neurocognitive 
disorders 
N (%) 
Substance-
related and 
addictive 
disorders 
N (%) 
Schizophrenia 
and other 
psychotic 
disorders 
N (%) 
Mood 
disorders 
N (%) 
Anxiety 
disorders   
N (%) 
Personality 
disorders 
N (%) 
Other 
disorders 
N (%) 
2006 1631 (7.8) 5451 (26.2) 6823 (32.8) 10510 (50.5) 2414 (11.6) 2024 (9.7) 2716 (13.0) 
2007 1368 (8.1) 4610 (27.3) 4683 (27.7) 8812 (52.1) 1931 (11.4) 1436 (8.5) 2085 (12.3) 
2008 1307 (8.5) 4121 (26.9) 3991 (26.1) 8212 (53.7) 1939 (12.7) 1331 (8.7) 1822 (11.9) 
2009 1245 (8.5) 3994 (27.2) 3875 (26.4) 7723 (52.7) 2050 (14.0) 1245 (8.5) 1835 (12.5) 
2010 1217 (8.8) 3902 (28.0) 3536 (25.4) 7525 (54.1) 2014 (14.5) 1121 (8.1) 1786 (12.8) 
2011 1208 (8.9) 3838 (28.2) 3477 (25.6) 7303 (53.8) 2095 (15.4) 1136 (8.4) 1803 (13.3) 
2012 1140 (8.5) 3648 (27.3) 3412 (25.5) 7192 (53.7) 2169 (16.2) 981 (7.3) 1781 (13.3) 
2013 1216 (9.2) 3598 (27.1) 3361 (25.3) 7114 (53.6) 2208 (16.6) 1022 (7.7) 1813 (13.7) 
2014 1139 (8.6) 3701 (28.0) 3265 (24.7) 7017 (53.1) 2251 (17.1) 1018 (7.7) 1983 (15.0) 
2015 1120 (8.9) 3605 (28.7) 3044 (24.2) 6759 (53.7) 2252 (17.9) 1016 (8.1) 1742 (13.9) 
2016 987 (7.8) 3548 (28.0) 3155 (24.9) 6380 (50.3) 1906 (15.0) 1046 (8.3) 2249 (17.7) 
TOTAL 13578 (8.5) 44016 (27.5) 42622 (26.6) 84547 (52.7) 23299 (14.5) 13376 (8.3) 21615 (13.5) 
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Table 28. Number and percentage of inpatients in each age category by year 
 
 
 
 
 
 AGE 
YEAR < 18 
N (%) 
18-24 
N (%) 
25-34 
N (%) 
35-44 
N (%) 
45-54 
N (%) 
55-64 
N (%) 
65+ 
N (%) 
2006 286 (1.4) 2389 (11.5) 3660 (17.6) 4681 (22.5) 4391 (21.1) 2485 (11.9) 2935 (14.1) 
2007 298 (1.8) 1948 (11.5) 2997 (17.7) 3625 (21.4) 3612 (21.4) 2050 (12.1) 2381 (14.1) 
2008 314 (2.1) 1899 (12.4) 2606 (17.0) 3008 (16.7) 3210 (21.0) 1893 (12.4) 2373 (15.5) 
2009 264 (1.8) 1857 (12.7) 2428 (16.6) 2715 (18.5) 3190 (21.8) 1915 (13.1) 2297 (15.7) 
2010 255 (1.8) 1967 (14.1) 2237 (16.1) 2430 (17.5) 2928 (21.0) 1908 (13.7) 2190 (15.7) 
2011 296 (2.2) 2072 (15.3) 2223 (16.4) 2299 (16.9) 2832 (20.8) 1758 (12.9) 2108 (15.5) 
2012 366 (2.7) 2165 (16.2) 2172 (16.2) 2124 (15.9) 2650 (19.8) 1795 (13.4) 2115 (15.8) 
2013 341 (2.6) 2360 (17.8) 2097 (15.8) 2125 (16.) 2395 (18.1) 1758 (13.3) 2190 (16.5) 
2014 362 (2.7) 2493 (18.9) 2146 (16.3) 1946 (14.7) 2351 (17.8)  1756 (13.3) 2150 (16.3) 
2015 313 (2.5) 2324 (18.5) 2155 (17.1) 1860 (14.8) 2100 (16.7) 1706 (13.6) 2122 (16.9) 
2016 357 (2.8) 2599 (20.5) 2183 (17.2) 1824 (14.4) 2107 (16.6) 1612 (12.7) 2003 (15.8) 
TOTAL 3452 (2.5) 24073 (15.0) 26904 (16.8) 28637 (17.9) 31766 (19.8) 20636 (12.9) 24864 (15.5) 
